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ABSTRACT 
 
Illicit drug use is an important cause of premature deaths globally. The purpose of this study was to 
assess deaths that occurred among treatment-seeking drug users in Greater Helsinki Area of Finland. 
Specifically, the study examined causes of deaths, potential years of life lost before 70 years, and the 
risk/association between the route of drug administration and all-cause deaths. 
     This study was conducted using the HUUTI (Huumehoitotietokanta) data, which contained medical 
records of 4817 consecutive drug-using clients (3365 males and 1452 females) aged 11-65 years that 
sought treatment at the Helsinki Deaconess Institute (HDI) between 31 January 1997 and 31 August 
2008. Their data were linked to the Finnish National Cause of Death Register and they were followed-
up from the first day of their first visit to HDI until death or 31 December 2010, whichever came first. 
     A total of 496 out of the 4817 clients (10.3%) died during the follow-up. Of these 496 deaths, 417 
(84.1%) occurred in male drug users and 79 (15.9%) in females. Deaths in the entire cohort were almost 
nine-fold of those that occurred in the general Finnish population of the same age and gender. This 
excess mortality was more pronounced among females than males. Overall, the most common causes of 
deaths were accidental overdose (165 deaths) and suicides (108 deaths), followed by deaths from 
mental and behavioural disorders (49 deaths) and circulatory system diseases (45 deaths).  
     It was observed that clients died prematurely at the average (mean) age of 33.8 years. The average 
(mean) potential years of life lost per decedent before the age of 70 years was 36.2 years. On average, 
female drug users lost more life years than their male counterparts but men lost the highest total 
number of life years. The two top-ranking causes of lost life years were accidental overdose and suicide.   
     Further analyses were carried out in a subset of 2766 clients who reported opiates (n=1432) and 
stimulants (n=1334) as their primary drug at baseline interview. Among clients whose routes of drug 
administration were specified, intravenous (I.V.) drug users had higher proportions of all-cause deaths 
(12.7%, n=251/1976), followed closely by oral users (11.5%, n=27/235) while smokers and snorters came 
a distant third (7.9%, n=12/152) and fourth (6.9%, n=19/276) respectively. The risk for all-cause death 
was lower among smokers compared to I.V. users (adjusted hazard ratio: 0.52 [95%CI: 0.28–0.97]) after 
adjusting for gender, homelessness, number of drug used, type of primary drug, past month frequency 
of using primary drug, and psychiatric problems present at initial visit.  
     This study demonstrated that prevention and intervention measures that address accidental 
overdose and suicide would be necessary in order to reduce untimely deaths among drug users, 
thereby stemming the preventable loss of potential future workforce. Gender-specific approaches will 
be required to address the treatment needs of female drug users. Granted that smokers had lower risk 
of all-cause death than injectors, it does not necessarily imply that smoking is a harmless way to use 
drugs. 
 
National Library of Medicine Classification: WA 900, WM 270 
Medical Subject Headings: Cause of Death; Cohort Studies; Drug Users; Finland; Follow-Up Studies; 
Registries; Sex Distribution; Street Drugs; Substance-Related Disorders/mortality 
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1 Introduction 
 
 
The annual drug report compiled by the Finnish National Focal Point highlighted an 
increase in the number of persons using illicit drugs in Finland in the last 15 years 
(Varjonen et al. 2014), and this has generated research interests in order to monitor the 
negative health consequences of drug use (Academy of Finland 2006). Death is the most 
serious of those negative consequences from illicit drug consumption. 
     Research conducted in international settings have shown that illicit drug users have 
increased risk of death compared to persons in the general population of the same sex and 
gender (Nyhlén et al. 2011; Bargagli et al. 2006). These deaths could arise from the direct 
effect of the consumed drug, for example, accidental overdose, or from more distal factors 
such as traffic accidents, assaults and cardiovascular diseases (Nyhlén et al. 2011; Merrall 
et al. 2012; Stenbacka et al. 2010). Drug users tend to die prematurely at an early age and 
as such, their deaths lead to loss of productivity in a society (Degenhardt et al. 2004). It has 
been reported that the route of drug administration is one of the factors that heavily 
influence the health risks associated with drug use (European Monitoring Centre for 
Drugs and Drug Addiction [EMCDDA] 2011a; Warner-Smith et al. 2001a), and  injecting 
poses  more risk than the other routes (Novak & Kral 2011). 
     Robust epidemiological studies on mortality among illicit drug users in Finland are 
scarce. Existing local mortality studies were limited by small sample size and focus on 
narrow subgroups such as drugged drivers, overdose cases, pregnant women, and users 
of prescription medication such as buprenorphine (Vuori et al. 2003; Karjalainen et al. 
2010; Simonsen et al. 2011; Salasuo et al. 2009; Vuori et al. 2012; Kahila et al. 2010; 
Häkkinen et al. 2012; Uosukainen et al. 2013a). At international level, researchers have 
generated mortality estimates for single types of drugs (Arendt et al. 2011; Calabria et al. 
2010; Degenhardt et al. 2011b; Singleton et al. 2009), and this method might not adequately 
account for multiple drug use which is common in treatment-seeking samples. Many of 
the existing mortality studies conducted in various international settings used traditional 
mortality indicators (for example, death counts, mortality rates, and standardised 
mortality ratio) which did not account for the prematurity of those deaths. Although 
people consume illicit drugs through different routes, previous research have 
predominantly focused on injectors. 
     Using a large cohort and data collected over a long period, the purpose of this study 
was to assess deaths that occurred among treatment-seeking illicit drug users. Specifically, 
the study examined causes of deaths, the prematurity of those deaths in terms of potential 
years of life lost before 70 years, and the association between the route of drug 
administration and all-cause deaths. For the purpose of this study the term “use” is 
defined as any use of psychoactive substance. This is because some of the clients in this 
study cohort did not use drug regularly and cannot be described as being drug dependent. 
Hence the general term “use” or “user” was used throughout this dissertation to refer to 
all the clients. In the dataset used for this study, all opiate/opioid drugs were grouped as 
opiates. Hence, this dissertation did not distinguish between opiates and opioids, and the 
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term “opiates” was used throughout in the text to refer to clients’ use of all opiate/opioid 
drugs except in the literature review section, where opioid or opiate was used as 
presented in the cited publication. 
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2 Literature review 
 
 
For the review of literature, various combinations of the terms ‘opioids’, ‘cannabis’, 
‘cocaine’, ‘amphetamine type stimulants’, ‘illicit drugs’, ‘illegal drugs’, ‘drug use’, ‘drug 
abuse’, ‘substance-related disorders’, ‘death’, ‘mortality’, ‘longitudinal studies’, and 
‘cohort studies’ were used to identify relevant English language publications in PubMed, 
MEDLINE, and PsychInfo. Papers were also found via searching credible sources on the 
Internet. Reference lists of systematic reviews and monograph on mortality among illicit 
drug users were manually searched to identify relevant studies. Some authors were 
contacted for full-texts of their papers. Consultation was made with the Library 
Information Specialist.  
 
 
2.1 OVERVIEW OF DRUG USE 
 
2.1.1 Global overview 
Globally, illicit drug use is an important public health problem because it is associated 
with substantial negative health consequences in terms of morbidity and mortality (Chen 
& Lin 2009; Degenhardt et al. 2011a). According to the recent global estimate (World Drug 
Report [WDR]) by the United Nations Office on Drugs and Crime (UNODC), 243 million 
persons or 5.2% of the world population aged 15–64 years had used illicit drugs at least 
once in 2012 (UNODC 2014). Figure 1 shows the global estimates of drug use during the 
2006–2012 time periods. At 177 million users, cannabis was the most predominant drug 
used globally in 2012, and the estimated number of users of the other drugs included 33 
million for opioids, 16 million for opiates, 17 million for cocaine, 34 million for 
amphetamine-type-stimulants, and 18 million for ecstasy (UNODC 2014).The primary 
drug of abuse varies from one region to another, and this is often reflected in the drug 
types contributing to drug treatment demands in each region (UNODC 2014).  
 
 
Figure 1. Global estimates of drug use, 2006–2012. Source: World Drug Report (UNODC 2014). 
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     The proportions of primary drugs of concern contributing to treatment demands in 
different regions are shown in Figure 2. In 2012, cannabis dominated the demand for 
treatment in Africa (above 60%), North America (nearly 40%), and Oceania (nearly 50%); 
cocaine was the predominant drug in Latin America and the Caribbean (nearly 50%); 
while opioids contributed more to treatment demands in Asia (about 60%), East and 
South-Eastern Europe (nearly 80%), and West and Central Europe (nearly 50%).  
     Poly/Multiple drug use (the use of two or more drugs) is common and drug use is 
generally higher among men than women (UNODC 2014). However, gender differences 
are not so distinct among persons who use pharmaceutical drugs for non-medical 
purposes – there may be equal proportions of users by gender, and it may be sometimes 
higher among females than males (UNODC 2014). A systematic literature review 
conducted by Mathers et al. (2008) reported that injecting drug use was identified in 148 
countries, with higher numbers of injectors found in China, USA, and Russia. More 
recently, UNODC, World Health Organization (WHO), Joint United Nations Programme 
on HIV/AIDS (UNAIDS), and the World Bank jointly estimated that in 2012, 12.7 million 
(or 0.27%) of the global population aged 15–64 years had recently injected drugs (UNODC 
2014; Gowing et al. 2015). The Eastern and South-Eastern Europe recorded the highest 
prevalence of 1.26% which was 4.6 times the global average of 0.27%, and this was driven 
by high rates of injecting drug use in Russia, Moldova, Belarus, and Ukraine (UNODC 
2014; Gowing et al. 2015). 
 
 
 
 
Figure 2. Primary drugs contributing to treatment demands in different regions, 2003–2012.  
Source: World Drug Report (UNODC 2014). 
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2.1.2 Illicit drug use in Europe 
Estimates of drug use in the European Union are compiled by the European Monitoring 
Centre for Drugs and Drug Administration (EMCDDA). The current European Drug 
Report (EDR) published by the EMCDDA documented that over 80 million Europeans had 
used illicit drugs at some point in their lives (EMCDDA 2015). The EDR showed that 
cannabis use is highly prevalent in Europe. It was estimated that 78.9 million persons aged 
15–64 years had used cannabis in their lifetime, and 19.3 million persons in this same age-
group used cannabis at least once during past year (EMCDDA 2015). The estimates of the 
use of other drugs, according to the EDR, are shown in Figure 3. Analyses of variations 
between countries showed an increasing prevalence of past year cannabis use among 
young adults (i.e. 15–34 year olds) in Bulgaria, France, and some Nordic (or northern 
European) countries including Finland (Figure 4). 
     In terms of treatment-seeking population, the proportions of persons entering treatment 
by primary drug are shown in Figure 5. Opioids contributed the most to treatment 
demand at specialised centres, followed by cannabis, and cocaine. Opioid users accounted 
for 41% of all treatment entrants in 2013 (EMCDDA 2015). Heroin is the predominant 
opioid used in Europe, even though the use of other opioids might be more problematic in 
different countries, for example, illicit fentanyl in Estonia and buprenorphine in Finland. 
Cocaine is the most commonly used stimulant in Europe, with over 70% of all cocaine 
treatment clients being reported by only three countries (Spain, Italy, and UK). Regarding 
the other stimulants, long-term use of amphetamine is more commonly reported in 
northern European countries while long-term use of methamphemine is more common in 
Czech Republic and Slovakia (EMCDDA 2015). 
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Figure 3. Estimates of drug use among 15–64 year olds in Europe for year 2015 report.  
Source: European Drug Report (EMCDDA 2015). 
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Figure 4. Last year prevalence of cannabis use among young adults (15–34 years), countries showing 
statistically significant increasing trends, 2000–2014. Source: European Drug Report (EMCDDA 2015). 
 
 
 
 
Figure 5. Proportions (percentages) of clients entering specialised drug treatment by primary drug,  
2006–2013. Source: European Drug Report (EMCDDA 2015). 
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2.1.3 Illicit drug use in Finland 
In Finland, illicit drug use is a more recent phenomenon that has grown in the last 15 
years, even though alcohol use and its related problems are far more common (Varjonen 
2015), and it was estimated that there were 11000–18000 problem amphetamine users and 
13000–15000 problem opioid users in Finland in 2012 (Ollgren et al. 2014). Finland Drug 
Situation (FDS) is an annual drug report by the Finnish National Focal Point which 
operates within the National Institute for Health and Welfare (THL). The FDS compiles the 
latest development and the most recent Finnish research on drugs and key indicators of 
the drug situation in Finland (Varjonen 2015). Drug use in Finland is similar to the 
patterns observed at global and European levels in terms of preponderance of lifetime 
cannabis users. According to the current FDS, the results of the 2010 population study 
showed that 17% of persons aged 15–69 years had used cannabis at some point in their 
lives, and lifetime prevalence for other drugs included 2.1% for amphetamines, 1.7% for 
ecstasy, 1.5% for cocaine, and 1% for opioids (Varjonen 2015). Earlier report of the 
population survey in 2010 showed an increase in drug use, especially for cannabis use, 
whereby lifetime cannabis use among 25–34 year olds increased from 25% in 2006 to 36% 
in 2010 (Hakkarainen et al. 2011). The report by Hakkarainen et al. (2011) also highlighted 
concerns about the mixed use of drugs, alcohol, and medicinal substances. This same 
concern was echoed by Tammi and colleagues who found that multiple drug use was 
common in a sample of 100 disadvantaged drug users in the Helsinki area, especially 
mixing of opioids, benzodiazepines, and alcohol (Tammi et al. 2011). More recently in 
2015, another report was published on the drug use trend using population surveys from 
1992–2014 (Hakkarainen et al. 2015). It was found that lifetime cannabis use statistically 
significantly increased from 5% in 1992 to 19% in 2014, while ecstasy use similarly 
increased from 0.3% in 1996 to 2.6% in 2014 (Hakkarainen et al. 2015). Changes in the use 
of other substances were not statistically significant.   
     As seen in Figure 3, the lifetime rates of drug use in Finland were below the lifetime 
estimates for 15–64 year olds in the European Union. In comparison to lifetime prevalence 
reported for individual countries in the current European Drug Report (EMCDDA 2015), 
Spain (10.3%) and UK (9.5%) exceeded Finland in cocaine use; UK (11.1%) and Denmark 
(6.6%) exceeded Finland in amphetamine use; UK (9.3%) and Ireland (6.9%) had higher 
ecstasy use, while France (40.9%) and Denmark (35.6%) had higher lifetime prevalence for 
cannabis use than Finland.  
     The picture is different among the treatment population. Figure 6 illustrates the 
primary drug among treatment entrants. Generally, opioids contributed more than half of 
the drug treatment demands in Finland (Varjonen 2015).  This showed that Finland was 
similar to Europe in terms of opioids contributing the most to treatment demand. 
Amphetamine is the predominant stimulant drug used by persons entering drug 
treatment in Finland (Varjonen 2015), and as seen in the current European Drug Report 
(EMCDDA 2015), 11% entrants to amphetamine treatment in Finland exceeded 6.7% in 
Europe.  In general, most (68%) of all the clients in contact with drug treatment services in 
Finland were men, and they tended to have low educational attainment, unemployed, and 
homeless. More than half reported problematic use of at least three substances and three-
quarters had injected drugs at some point in their lives (Varjonen 2015). These data 
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reported by Varjonen 2015 were corroborated by those reported by Forsell and Nurmi 
(2015). Based upon 2014 data from 86 drug treatment units, it was found that 66% of the 
1891 drug treatment clients were men, 61% were in the 20–34 age group, their educational 
level was low, 9% were homeless, 77% were intravenous (I.V.) users and 66% used 
multiple drugs in the previous month (Forsell & Nurmi 2015). The report by Forsell and 
Nurmi (2015) provided an update of information in Figure 6 by showing the choices of 
primary drugs for years 2013 and 2014; as seen in Figure 7, opioids clearly retained its 
position as the most common primary substance among treatment seekers. 
 
 
Figure 6. Primary substances used by clients entering treatment for the use of illicit drug and 
pharmaceuticals (percentage of clientele) in 2000–2012). Source: Finland Drug Situation (Varjonen 2015). 
 
 
     Given the dominant role of opioids in drug treatment demand, it is important to 
mention that buprenorphine is the predominant opioid used in Finland (Varjonen 2015). 
Using preliminary data on I.V. drug use among 176 I.V. drug users in Helsinki in 2005, it 
was found that nearly three-quarters (73.2%) of the respondents frequently injected 
buprenorphine (Alho et al. 2007). This was corroborated by the results reported by 
Simojoki (2013), and by Simojoki and Alho (2013) in their study of 1507 attendees at 10 
harm reduction (needle and syringe exchange) units in Helsinki from 2000-2008, and 2010. 
They found that the percentage of the study participants who reported heroin and 
morphine as their first injected drug declined from 60.2% in 2007 to 51.3% in 2010, while 
those reporting buprenorphine rose from 30.5% in 2007 to 44.4% in 2010 (Simojoki 2013; 
Simojoki & Alho 2013). Similarly, Uosukainen and colleagues also found that among 
treatment seekers, buprenorphine users overtook heroin users after 2001, and that the 
percentage of buprenorphine users rose from 3.0% in 1998 to 38.4% in 2008 (Uosukainen et 
al. 2013b). The drop in heroin use may be connected to substantial drop in supply starting 
from 2001 due to reduction in heroin production in Afghanistan (Partanen & Mäki 2004). 
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Hence, it is evident that while heroin is problematic at the European level, buprenorphine 
is problematic in Finland. 
 
 
Figure 7. The drug treatment clients the primary problem substance in the period 2000–2014  
[päihdehuollon huumeasiakkaiden ensisijainen ongelmapäihde vuosina 2000–2014]. 
Source: Päihdehuollon huume-asiakkaat 2014 (Forsell & Nurmi 2015). 
 
 
      A novel approach using wastewater analysis (i.e. waste water or sewage examined for 
drug metabolites) has provided further insights into drug use in different parts of Finland. 
Using 24-hour influent composite samples from wastewater treatment plants, Kankaanpää 
et al. (2014) analysed for the use of illicit stimulants in 10 major cities located in different 
geographical areas which covered 40% of the population of Finland. They found that 
amphetamine dominated the drug scene because it was the most commonly used drug in 
all the 10 cities (Kankaanpää et al. 2014). The use of illicit stimulants was more common in 
southern Finland. Cocaine use was generally far less common, and it was not detected in 
northern cities of Oulu and Rovaniemi. High amounts of the new psychoactive 
substance/designer drug MDPV (Methylenedioxypyrovalerone) was observed in the 
Lapperanta region. Interestingly, significant variations in the use of cocaine and MDMA 
(3,4-methylenedioxy-methamphetamine or ecstasy) by weekday was observed; they were 
most often used at the weekends (Kankaanpää et al. 2014).  
     Using similar methodology of wasterwater analysis, Vuori et al. (2014) also found that 
amphetamine was the most prevalent drug in the nine towns and cities studied. Cocaine 
use was low, heroin metabolite (6-Monoacetylmorphine) was not detected in any 
towns/cities, and the use of cannabis and all other illicit drugs was minimal in the rural 
towns of Seinäjoki and Savolinna (Vuori et al. 2014). Similar to Kankaanpää et al.’s finding, 
the use of cocaine and ecstasy was higher during the weekends, while other stimulants, 
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cannabis, and opioids had more constant concentrations during the week (Vuori et al. 
2014). 
      In view of the drug situation over the years, some of the drug attitudes among Finnish 
people also changed. In the review of findings from general population surveys during 
1992–2010, Metso and colleagues noted a shift in attitudes and opinions. They found that 
there were less fears and that attitudes were relaxed towards cannabis use but not to the 
use of other substances (Metso et al. 2012). More so, their results demonstrated public 
support/approval for measures such as substitution treatment and needle exchange 
programmes with health counselling (Metso et al. 2012). 
 
 
2.2. HEALTH CONSEQUENCES OF DRUG USE – MORTALITY  
 
Drug use is associated with adverse health outcomes and untimely death is the most 
serious consequence. Synthesis of evidence from different cohort studies has shown that 
deaths tend to occur in mid-thirties (Giraudon et al. 2012), even though the age of death 
could vary depending on the age composition of the cohort.  Generally, the numbers of 
deaths are often higher among male drug users than females since males tend to be higher 
in number than females in many cohort studies (Giraudon et al. 2012). Most cohort studies 
reported crude mortality rates (CMRs) within the range of 10–20 per 1000 per year 
(Giraudon et al. 2012). However, drawing upon primary research data from the analysis of 
mortality among drug users recruited from drug treatment centres in eight European 
countries (Ireland, United Kingdom, Spain, Italy, Denmark, Portugal, Austria, and the 
Netherlands), Bargagli et al. found that CMR differed by settings – it was as high as 37.60 
per 1000 person-years (PY) in Dublin, Ireland and as low as 11.02 per 1000PY in Barcelona, 
Spain (Bargagli et al. 2006). Overall/all-cause CMR tend to be higher for male drug users 
than females in general (Bargagli et al. 2006; Arendt et al. 2011; Ødegård et al. 2007; Evans 
et al. 2012), and higher in males than females of the same age-group (Ødegård et al. 2007). 
      Mortality among drug users is a major public health concern because they die earlier 
and experience more deaths than their gender and age-group peers in the 
background/general population. This excess mortality among drug users has been 
documented in various cohort studies, with overall all-cause standardised mortality ratio 
(SMRs) ranging from 3.4 to 26.0 (Table 1). In many studies conducted in different 
populations, overall all-cause SMR tends to be higher among female drug users than their 
male counterparts (Bargagli et al. 2006; Rehm et al. 2005; Arendt et al. 2011; Ødegård et al. 
2007; Pierce et al. 2015; Gibson et al. 2011; Stenbacka et al. 2010; Jimenez-Treviño et al. 
2011; Fugelstad et al. 2014; Evans et al. 2012; de la Fuente et al. 2014; Lee et al. 2013; Kuo et 
al. 2011). The possible reason for this higher SMR among females than male drug users is 
due to fewer deaths among women in the general population (Stenbacka et al. 2010). In 
terms of age-groups, SMRs are often higher in younger age-group than in the older age-
group (Ødegård et al. 2007; Nyhlén et al. 2011), possibly due to fewer deaths among 
young persons in the general population. 
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2.3 CAUSES OF DEATHS 
 
The causes of deaths fall into two broad categories namely drug-induced deaths (DID) and 
non-drug induced deaths (non-DID). DID and non-DID generally refer to deaths that are 
directly and indirectly caused by drug use respectively. The nature and specific causes of 
deaths in each of these two categories are presented in subsections 2.3.1 and 2.3.2. Causes 
of deaths from  longitudinal cohort studies involving drug users in contact with drug 
treatment services during the last 10 years have been summarised in Table 1. 
 
2.3.1 Drug-induced deaths 
Randall et al. (2009) adopted their definition of DID from the Australian Bureau of 
Statistics which defined DID as “deaths where the underlying cause of death is directly 
attributed to drug use” (Australian Bureau of Statistics 2006, explanatory note: item 2). 
They derived this definition of DID from the following 10th International Classification of 
Diseases (ICD-10) code combinations:  F11-F16, F19 (mental and behavioural disorders 
due to psychoactive substance use (excluding alcohol, tobacco and volatile solvents, e.g. 
petrol), F55 (abuse of non-dependence-producing substances), X40-X44 (accidental 
poisoning by drugs, medicaments and biologicals), X60-X64 (intentional self-harm by 
drugs, medicaments and biologicals), X85 (assault by drugs, medicaments and biological 
substances), and Y10-Y14 (deaths by undetermined intent by drugs, medicaments and 
biologicals). Other researchers (e.g. Merrall et al. 2012) have used the same ICD-10 code 
combinations and called them “drug-related deaths”.  
     DID such as accidental poisoning/overdose is the dominant cause of death among drug 
users, and this has been documented in many mortality studies using different study 
designs and populations (Bartu et al. 2004; Clausen et al. 2009; Degenhardt et al. 2014; 
Evans et al. 2012; Fugelstad et al. 2014; Gibson et al. 2011; Merrall et al. 2012; Ødegård et 
al. 2007; Pierce et al. 2015; Ravndal et al. 2015; Ravndal & Amundsen 2010; Solomon et al. 
2009; Maxwell et al. 2005; Darke et al. 2011; Zábranský et al. 2011). Darke and colleagues 
(Darke et al. 2007) provided a comprehensive review of mortality among illicit drug users 
based upon research studies spanning 1968–2005; it was found that overdose deaths were 
chiefly reported among opioid and cocaine users while cannabis use is not a known cause 
of overdose death (Darke et al. 2007). The mechanisms of overdose death vary according 
to the type of drug. It is primarily due to respiratory depression in opioid users, and the 
mechanism in cocaine and amphetamine users relates primarily to myocardial infarction 
possibly due to elevated oxygen demands and other cardiovascular complications (Darke 
et al. 2007). In users of MDMA, hyperthermia (i.e. elevated body temperature) is the major 
mechanism of overdose deaths; other mechanisms include excessive water consumption 
resulting in cerebral edema, cardiovascular complications, and liver failure (Darker et al. 
2007). 
 
2.3.2 Non-drug induced deaths 
Non-DIDs (also known as non-drug related deaths) denote ICD-10 codes other than those 
for DID. As seen in mortality studies presented in Table 1, causes of deaths other than 
overdose include suicide (or intentional self-harm), traffic accidents, assaults, 
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cardiovascular disease, various types of infections, and so on.  Causes of deaths in this 
subgroup are due to indirect consequences of using drugs. For example, drug use is 
known to increase the risk of suicide. A study conducted in the US (Kung et al. 2003) 
found that drug use was one of the factors that elevated the odds of dying from suicide. 
Similarly, a 5-year follow-up of 1198 deliberate self-harm patients in Finland  found that 
having a diagnosis of a substance use disorder was one of the risk factors for both suicide 
and all-cause death (Suominen et al. 2004). Drawing upon synthesis of evidence from  
studies on different causes of mortality, the methods of committing suicide vary from 
violent methods such as shooting and hanging among male drug users, to non-violent 
methods such as overdose with drugs among females (Darke et al. 2007). 
Assault/homicide/murder tends to be high among drug users. Researchers found 
excessive risks of death from homicide/assault among drug users relative to the general 
population of Scotland (Merrall et al. 2012) and England (Pierce et al. 2015), and it 
accounted for more than half of the deaths in two Brazilian studies (Dias et al. 2011; 
Ribeiro et al. 2006). Assaults might be due to drug dealing, drug-induced aggressive 
behaviours or being attacked while under the influence of drugs (Neale et al. 2005), or 
other crimes and sex work which expose drug users to violence (Darke et al. 2007). 
     HIV is high among drug users due to sharing of used injecting equipment and 
unprotected sex – data from 2007/2008 showed that 3 million injectors globally were 
estimated to be HIV positive (Mathers et al. 2008), though the adult prevalence of HIV in 
Finland in 2011 was 0.1% (Avert 2015). However, the advent of highly active antiretroviral 
therapy (HAART) has reduced the impact of HIV as a major cause of mortality among 
drug users. This is reflected in studies conducted in different parts of the world whereby 
the proportion of HIV/AIDS deaths is higher in cohort studies with follow-up periods 
covering pre-HAART era of 1990s [e.g. 52.8% of the total deaths observed in an Italian 
cohort by Manfredi et al. (2006)], compared to those of post-HAART era of years [e.g. 
16.5% of total deaths observed in an India cohort by Solomon et al. (2009)]. Liver diseases 
make substantial contribution to mortality among drug users (Degenhardt et al. 2014; 
Gibson et al. 2011; Maxwell et al. 2005). For example, blood-borne viral liver infection like 
hepatitis C virus infection (HCV) is highly rampant among injecting drug users, and based 
upon data from 2010/2011 it is estimated that about 10 million injectors worldwide have 
HCV positive status (Nelson et al. 2011). Some studies have reported HCV transmission 
through sharing of non-injecting paraphernalia like straws, tubing, and pipes (Caiaffa et 
al. 2011; Tortu et al. 2004). Heavy use of alcohol in the presence of liver disease accelerates 
the progression to complications due to extra stress on the liver (Gibson et al. 2011). 
     Historically, research studies have mainly focused on drug-induced deaths. However, 
medical problems such as cardiovascular diseases and pneumonia have been reported as 
causes of deaths among drug users (Stenbacka et al. 2010; Degenhardt et al. 2014; Merrall 
et al. 2012; Pierce et al. 2015; Clausen et al. 2009; Maxwell et al. 2005). The mechanisms of 
these deaths could be explained in different ways. Drugs like cocaine, ecstasy and 
amphetamines stimulate the sympathetic nervous system and predispose to myocardial 
infarction and other complications of the circulatory system (Ghuran et al. 2001). Drug 
users are predisposed to pneumonia due to bacteria and other pathogens introduced into 
the body from injecting contaminated drugs, infections at injection sites, or aspiration 
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resulting from depression of the normal coughing and sneezing reflexes by drugs such as 
opiates (Del Giudice 2004; Gotway et al. 2002). 
 
2.3.3 Avoidable deaths 
Irrespective of whether the cause of death was DID or Non-DID, some of the deaths could 
be avoided. Donaldson and Scally (2009) described avoidable deaths as deaths from causes 
and within age groups that might have been avoided by preventive measures or better 
clinical management. In their Australian and New Zealand Atlas of Avoidable Mortality, 
Page et al. (2006) described avoidable mortality as causes of deaths that are potentially 
avoidable at the present time given available knowledge about social and economic policy 
impacts, health behaviours and healthcare. Page and colleagues’ broad classification of 
avoidable mortality included 12 major condition groups namely infections; cancers 
(malignant neoplasms); nutritional, endocrine and metabolic conditions; drug use 
disorders; neurological disorders; cardiovascular disorders; genitourinary disorders; 
respiratory diseases; digestive; maternal and infant causes; unintentional injuries; and 
intentional injuries (Page et al. 2006). 
     Avoidable causes of death could be either “amenable” causes or “preventable” causes. 
According to Page et al. (2006), amenable conditions are those causes of death whose case 
fatality could be reduced by timely and effective treatment using currently available 
healthcare technology.  Preventable conditions are those causes of deaths that are 
responsive to prevention at the individual and population level through lifestyle change, 
environmental modification or health policy (Page et al. 2006). However, this 
dichotomisation of avoidable mortality into amenable and preventable subgroups might 
be challenging for some conditions such as ischaemic heart diseases, cerebrovascular 
disease, and diabetes. This is because addressing deaths from these conditions would 
require both public health interventions for incidence reduction and medical care to treat 
established diseases (Page et al. 2006). Others have opted to use only one single term 
“amenable mortality” which they defined as “causes of death for which mortality rates are 
likely to reflect variations in the effectiveness of health care, with health care being limited 
to primary care, hospital care, personalised public health services (e.g. immunisation and 
screening)” (Plug et al. 2011, pg.6: results).  
     Generally, mortality is considered avoidable if it occurs within a certain age limit, e.g. 
0–74 years; deaths beyond 75 years tend to have high levels of multiple comorbidities 
thereby posing challenges to categorisation of causes of deaths into avoidable or non-
avoidable causes (Page et al. 2006). This 75-year age limit is also used in Canada (Canadian 
Institute for Health Information [CIHI] 2012). Unavoidable mortality refers to “deaths 
occurring before age 75 from causes that are considered both (a) not amenable to medical 
intervention and (b) not preventable through changes in individual behaviour/public 
health measures. Examples include cancers of the pancreas, ovary, and prostate” (Pevalin 
2015, Mortality type definitions section: unavoidable mortality).  
     Avoidable mortality is an important indicator in terms of health policy as it draws 
attention to health areas that require improvement. It provides insight into the 
performance of the health system. However, such mortality can be influenced by different 
factors in addition to health care effectiveness, therefore, policy makers must not solely 
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use it to judge the effectiveness of the health care system (Plug et al. 2011). In the words of 
Kossarova and colleagues, “to date the indicator was intended to point towards areas 
which require further investigation into health service provision and not as an absolute 
measure of outcome” (Kossarova et al. 2009, pg.12: section V). Estimation of avoidable 
mortality is necessary because such information helps to identify focus for further 
investigation or for targeted action so as to reduce untimely deaths (Donaldson & Scally 
2009).  
     Avoidable mortality is based on the concept that premature deaths from certain 
conditions should not occur in the presence of timely and effective healthcare (Office for 
National Statistics [ONS] 2014). Unlike overall mortality statistics, avoidable mortality 
only applies to causes of death where the mechanisms of reducing such deaths are known 
which makes it possible to take actions to address them (CIHI 2012). Comparability of 
findings of avoidable mortality across different studies and countries might be 
challenging. This is due to factors such as differences in the lists of conditions of death 
considered avoidable, the age limit used, and certification and coding of deaths 
(Kossarova et al. 2009; Nolte & McKee 2004). Therefore, interpretation of results and 
conclusions of such comparisons requires caution. Based upon systematic review of 
several papers, it was found that avoidable mortality varies by social groups such that 
socially disadvantaged population groups tend to have higher avoidable mortality (Nolte 
& McKee 2004). Since drug users are a socially disadvantaged group (Galea & Vlahov 
2002), it is expected that the rate of avoidable mortality in this population will be high.   
     A recent study among drug users has estimated avoidable mortality using Page et al.’s 
taxonomy of conditions. In this study, Degenhardt et al. (2014) analysed the data for a 
large cohort of 43789 Australian drug users treated for opioid dependence to estimate the 
extent of avoidable mortality that occurred during the follow-up period, regardless of 
whether it was amenable or preventable subtypes. They found that 88% of all the cohort 
deaths were from potentially avoidable causes (Degenhardt et al. 2014), and the 
proportion of avoidable mortality among men (89%) was slightly higher than that of 
women (86%).  Avoidable conditions such as drug overdoses and suicides were prominent 
causes of death in that cohort (Degenhardt et al. 2014).  
 
2.3.4 Mortality and drug type 
Some researchers have focused on mortality among persons who used a specific drug. For 
example, in a systematic review and meta-analysis of cohort studies, Degenhardt et al. 
(2011b) reported excess mortality among opioid-dependent persons with pooled SMR of 
15.  Singleton et al. (2009) conducted a comprehensive systematic literature review on 
mortality among amphetamine users; although paucity of data and heterogeneity of the 
articles did not allow for pooled estimate of mortality, an overall SMR of 6.22 was reported 
among the Czech cohort. Calabria et al.’s systematic review did not yield clear evidence 
about cannabis use elevating all-cause deaths due to paucity of studies on the topic 
(Calabria et al. 2010).  A register-based Danish study provided further insights into 
mortality in persons using specific drugs. Using data for 20581 persons treated for illicit 
drug use in Denmark during 1996–2006, Arendt et al (2011) found significant excess 
mortality among various users with the following SMRs: 9.1 among heroin users, 7.7 
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among other opioid users (including illegally acquired opioids such as morphine, 
methadone, and buprenorphine), 6.4 among cocaine users, 6.0 among amphetamine users, 
4.9 among cannabis users, and 2.7 among ecstasy users. 
     While mortality estimates by drug type is informative, its practical application might be 
in doubt because drug users, especially those in contact with drug treatment services, tend 
to have risky drug use behaviours including mixing of different drugs. Using data for 393 
autopsied patients, Swedish researchers (Brådvik et al. 2009) found a significant linear 
relationship between multiple drug use and accidental overdose, and such deaths (i.e. 
accidental overdose deaths) are known to be common among drug users. In Finland, there 
is an increasing trend of pregabalin findings in the post mortem toxicology and this 
further highlighted the importance of multiple drug use as a risk factor for overdose death 
(Vuori et al. 2012). The different drugs synergise to produce health harms resulting in 
death. For example, the respiratory depressant effect of central nervous system 
depressants like alcohol and benzodiazepine is potentiated when consumed with heroin 
thereby resulting in overdose (Darke et al. 2007). However, when alcohol is combined with 
cocaine, the risk of death stems from the formation of cocaethylene which is more toxic 
than either substance used alone, and this cocaethylene was detected in 76% of cocaine-
related sudden deaths in Spain (Lucena et al. 2010). 
     In view of this, mortality estimates for specific drugs might not adequately account for 
multiple drug use especially in a treatment-seeking population. Instead, generating a 
single mortality estimate for the combined drug users would be a better approach in order 
to account for the effect of multiple drugs. 
 
 
2.4 PREMATURITY OF DEATHS AMONG DRUG USERS  
 
In longitudinal studies, researchers often estimate mortality in a cohort using traditional 
indicators such as frequencies/death counts, CMRs, and SMRs. The death counts merely 
tell the number of persons who died. The CMR is a measure of the number of deceased 
persons in relation to the person-years of observation while SMR is a ratio of observed 
deaths in the cohort to the expected deaths in a reference population. However, these 
traditional indicators of mortality are limited because they do not account for the 
prematurity of those deaths. Premature death is an economic loss to the society in terms of 
loss of potential workforce. The society loses more from drug users who died at an early 
age relative to those who died at older age (Smyth et al. 2007). Hence, a mortality measure 
that accounts for age at death would offer a better reflection of the impact of untimely 
deaths among drug users on the society than solely using the traditional indicators.  
     The potential years of life lost (PYLL) is a unique method for assessing premature loss 
of life. PYLL estimates the average time an individual would have lived if he/she had not 
died prematurely (Gardner & Sanborn 1990). Premature death means “deaths that occur 
earlier than the age of the average life expectancy of the population or before some 
selected age” (Šemerl & Šešok 2002, pg. 439). The selected age cut-off differs. Researchers 
from USA and Australia have used 65 years cut-off age (Smyth et al. 2007; Degenhardt et 
al. 2014). The Organisation for Economic Co-operation and Development (OECD) uses 70 
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years cut-off age for estimating PYLL (OECD 2014), and health policy experts in Finland 
have also used 70 years cut-off age for PYLL estimation in the general population of 
Finland (Vohlonen et al. 2007). 
     PYLL offers additional perspective to mortality even though only few studies among 
drug users have gone beyond estimating mortality with traditional indicators. In a study 
of 581 heroin users admitted to California Civil Addict Program in USA followed-up over 
33 years, Smyth et al. (2007) found that the 282 deceased persons lost an average of 18.3 
years per person before 65 years. Ranking of the individual causes of death showed that 
heroin overdose contributed 22.3% of the total PYLL, chronic liver disease contributed 
14%, while accidents ranked third by contributing 10.2% of the total PYLL (Smyth et al. 
2007). Australian researchers quantified PYLL before 65 years among 43789 persons 
attending opioid substitution treatment during the 1985–2005 in New South Wales, 
Australia (Degenhardt et al. 2014). They found that 3685 deaths occurred during the 
follow-up period, and the average life years lost by each deceased person was 29 years. 
Based upon the percentage contribution to the total PYLL, accidental opioid overdose was 
the topmost-ranking cause of premature loss of life as it contributed nearly half of the total 
PYLL (45%) while suicide contributed 13.6% (Degenhardt et al. 2014).  
     It is evident from these studies that PYLL enables estimation of both total life years lost 
and ranking of contributions of individual causes of death to the total loss. Therefore, 
PYLL is useful for highlighting priority areas for targeting public health prevention and 
intervention efforts in order to reduce future premature deaths.  
 
 
2.5 MORTALITY AND ROUTE OF DRUG ADMINISTRATION 
 
The route of drug administration (ROA) is one of the factors that substantially influence 
the health risks associated with drug use (EMCDDA 2011a; Warner–Smith et al. 2001a). 
Injecting poses more risk than the other routes (Novak & Kral 2011), and this is because 
injecting provides the fastest rate of absorption which allows a greater quantity of drug to 
reach the brain more rapidly  via the blood stream compared to other routes thereby 
increasing the likelihood of overdose (EMCDDA 2010a; Novak & Kral 2011). 
Consequently, mortality among injectors has received considerable research attention and 
researchers have conducted literature review in order to provide comprehensive synthesis 
of evidence on deaths among injectors (Degenhardt et al. 2006; Mathers et al. 2013; 
Mathers & Degenhardt 2014).  
     However, not all drug users inject their drugs and persons using drugs via non-
injecting ROA are not a homogenous group because some of them ingest the drug orally 
while others smoke or snort the drugs. Although injectors have increased risk of dying 
from both acute and chronic causes relative to non-drug users (Mathers & Degenhardt 
2014), consuming drug through any ROA has deleterious health consequence. For 
example, when cocaine is used regularly through any route, it may cumulatively elevate 
the risk of cardiac arrest owing to the accumulated cardiac damage, and the same is true 
for amphetamine use (Darke et al. 2007).  
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     Deaths among drug users based upon the various individual ROA (other than injecting) 
do not appear to generate a lot of research interests. In a study examining coronial files for 
cases of fatal heroin overdose in New South Wales, Australia during 1992–1996 period, 
Darke and Ross (2000) found that one percent of the cases (i.e. 10 out of 953 deaths) 
occurred among those who consumed drugs through non-injecting ROA. Of these 10 cases 
of overdose deaths via non-injecting ROA, smoking was the ROA in four cases, snorting in 
four cases, and oral ingestion in two cases (Darke & Ross 2000). A similar study of heroin 
overdose was conducted in Sweden. Thiblin et al. (2004) found that nearly eight percent of 
the cases of heroin overdose deaths (i.e. 18 out of 239 deaths) that occurred in Swedish 
drug users during 1997–2000 were associated with non-injecting ROA. These 18 deaths 
included 11 among heroin snorters and seven among heroin smokers (Thiblin et al. 2004). 
In a prospective cohort study involving 821 HIV-negative persons admitted for opiate or 
amphetamine detoxification treatment in northern Thailand during 1999–2002, Quan et al. 
(2007) found that 22 out of the total 33 deaths occurred among injectors while 11 deaths 
occurred among non-injectors. However, these 11 deaths were not disaggregated into the 
individual non-injecting ROA such as snorting, smoking, or oral ingestion.  
     From these studies, it is evident that there is no safe way to use drug even though that 
injectors tend to be disproportionately affected. Investigating deaths by various ROA will 
help to highlight the harms inherent in using drugs through injecting as well as individual 
non-injecting routes, and could be helpful for planning interventions targeted at route-
specific complications of drug use. 
 
 
2.6 MORTALITY SITUATION IN FINLAND 
 
In their study of deaths in four individuals, Vuori and colleagues found that their deaths 
occurred following the ingestion of MDMA and moclobemide (Vuori et al. 2003). Kahila et 
al. (2010) followed-up 524 women with alcohol and/or drug use during pregnancy for an 
average of nine years, and compared long-term morbidity, mortality, and welfare in the 
524 cases to a control group of 1792 non-substance using women. They found that 7.9% of 
the cases and 0.2% of the control died at the end of the follow-up (Kahila et al. 2010). 
Karjalainen et al. (2010) investigated mortality among 5832 drugged drivers followed-up 
during 1993–2006, and compared it to a reference group of 74809 individuals drawn from 
the general population of Finland. They found that the risk of death was nearly 10 times 
higher among the drugged drivers than in the reference population, and the most common 
cause of death in both genders was suicide.  Excess risk of death from cardiovascular 
diseases, cancer, and other diseases, and traffic accidents were higher among drugged 
drivers than the reference population (Karjalainen et al. 2010). 
     Mortality among opioid users has received considerable attention. Analysis of post-
mortem toxicological data on opioid-related deaths in Finland during 2000–2008 revealed 
that buprenorphine use was present in 391 out of the 1363 opioid-positive cases (Häkkinen 
et al. 2012). It was found that 47% of those buprenorphine-positive cases died from 
buprenorphine poisoning/overdose (Häkkinen et al. 2012). Uosukainen and colleagues 
found that buprenorphine users had a 7-fold risk of death (SMR of 7.3) compared to the 
19 
 
 
 
general population of Finland, and the SMR was higher in women buprenorphine users 
than men across all age-groups (Uosukainen et al. 2013a). The dominant role of 
buprenorphine in deaths from fatal poisonings in Finland differed from the situation 
elsewhere. Comparison with other Nordic countries in 2007 revealed that unlike in 
Finland, heroin/morphine was the most common drug in fatal poisonings in Norway and 
Sweden, methadone in Denmark, while heroin/morphine and methadone contributed 
equally to fatal poisonings in Iceland (Simonsen et al. 2011).  
     Using data from forensic investigations on drug-related deaths of 234 persons, Salasuo 
et al. (2009) reported that the number of drug-related deaths in Finland in 2007 was higher 
than in the preceding years. Accidental overdose arising from opioid use (especially 
prescription opioids) made substantial contributions to those drug-related deaths while 
amphetamines played lesser roles than opioids in those accidental overdose deaths 
(Salasuo et al. 2009). The results also highlighted the presence of multiple drug use among 
the deceased persons, especially joint use of benzodiazepines, alcohol, and other 
substances. Vuori et al. (2012) also investigated trends in forensic post mortem toxicology 
findings, and they found some changes in the number of fatal poisonings detected in 
Finland during 2008–2010. There were 1213 cases of fatal poisonings in 2008, 1211 cases in 
2009, and 1048 cases in 2010 (Vuori et al. 2012). The authors attributed the relatively low 
number in 2010 to reductions in the number of both alcohol and drug poisonings. Opioids 
maintained a dominant position, and opioid-related deaths involved mainly 
buprenorphine, and other opioids like tramadol, codeine, fentanyl, methadone, or 
oxycodone. During this 2008–2010 period, MDPV was the most common designer drug 
detected in the forensic data, and it was first detected in 2009 (Vuori et al. 2012).  
 
 
2.7 REGISTER-BASED STUDY 
 
2.7.1 Finnish health registers and research 
The use of registers in research in Finland provides a cost-effective access to good quality 
data because it reduces the cost and time spent on collecting research data (Gissler & 
Haukka 2004). The Finnish health register system has good coverage and validity (Gissler 
& Haukka 2004). It provides an opportunity to link data to different registers in order to 
perform research that will be beneficial to the society (Kajantie et al. 2006). 
Registers/administrative data contain large numbers of observations which permit the 
assessment of both rare and common outcomes in the population covered (Virnig & 
McBean 2001), and help to deal with loss to follow-up inherent in a conventional follow-
up study (Roos & Nicol 1999). 
     Data linkage for research purposes is possible due to the unified personal identification 
number system used in Finland (Kajantie et al. 2006). However, these registers contain 
sensitive health information and have raised privacy concerns (Lehtonen 2002). 
Consequently, identifying information is removed from the dataset given to researchers in 
order to prevent violation of privacy and confidentiality (Gissler & Haukka 2004). More 
so, the registers are protected by legislation so that persons wishing to access the data for 
research purposes undergo rigorous procedures such as ethical committee review, 
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application for permission from register controlling authorities and so on (Kajantie et al. 
2006; Finnish Information Centre for Register Research 2015). Similar measures of 
removing names and personal identifiers, and strictly controlling access to registers in 
order to maintain confidentiality are also practiced in other countries (Roos & Nicol 1999). 
     Unlike primary data obtained through direct observation/interview and strictly 
produced to address a particular research problem, data contained in registers were 
originally meant for some other purposes and are, therefore, secondary data (Sund 2003). 
Researchers could encounter several challenges when using secondary data. For example, 
health data may not contain some clinical information important for research such as 
laboratory results, and clinical measurements like blood pressure, height, weight, and so 
on (Virnig & McBean 2001). Secondary data might not be helpful for answering some 
research questions because some outcomes of greatest interests may not be available 
(Huston & Naylor 1996). Data from secondary sources could pose challenges to the 
research work such that some research questions might be unduly influenced or restricted 
by the availability of data (Huston & Naylor 1996; Sund 2003). 
 
2.7.2 Cause of Death Register 
The Cause of Death Register is maintained by Statistics Finland, and it is used to monitor 
deaths of Finnish residents either in Finland or abroad during the year (Kajantie et al. 
2006). In this register, an underlying cause of death is regarded as “the disease which has 
initiated the series of illnesses leading directly to death, or the circumstances connected 
with an accident or an act of violence which caused the injury or poisoning leading to 
death” (Statistics Finland 2010, definitions section: the causes of death). Since 1996, the 10th 
version of the International Classification of Disease (ICD-10) codes by the World Health 
Organization has been used for classifying causes of deaths (Kajantie et al. 2006). 
 
 
2.8 RATIONALE FOR THE STUDY 
 
Illicit drug abuse research is advanced internationally. However, in Finland there has been 
more extensive research on alcohol abuse than illicit drug abuse. This is because “alcohol 
use and related problems have traditionally been far more common than drug use and 
related problems” (Varjonen et al. 2014, pg. 26). Clients in contact with drug abuse 
treatment services provide useful data to undertake epidemiological research studies 
among Finnish illicit drug users. Their anonymised health records offer good quality data 
and relatively large cohort which can be followed longitudinally to answer relevant 
research questions without huge financial costs to the researchers and without breaching 
clients’ privacy.  
     Death is the most serious negative health outcome among illicit drug users. Robust 
epidemiological studies on mortality among illicit drug users in Finland are scarce. The 
few existing local studies are limited in various ways. Vuori et al. (2003) investigated 
deaths in four persons following the ingestion of MDMA and moclobemide but their 
study was limited by extremely small sample size. Other existing local mortality studies 
were limited by their focus on narrow subgroups such as drugged drivers (Karjalainen et 
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al. 2010), toxicological cases of overdose (Simonsen et al. 2011; Salasuo et al. 2009; Vuori et 
al. 2012), pregnant women (Kahila et al. 2010), and users of prescription medication such 
as buprenorphine (Häkkinen et al. 2012; Uosukainen et al. 2013a).  
     At international level, many studies have investigated deaths among illicit drug users, 
especially using treatment-seeking samples, and they have generated mortality estimates 
for different types of drugs (Arendt et al. 2011; Calabria et al. 2010; Degenhardt et al. 
2011b; Singleton et al. 2009). However, multiple drug use is rampant among treatment-
seeking population who are often heavy drug users, and it is likely that the different drugs 
acted in synergy to produce the health harm leading to death. To address this limitation, it 
will be more appropriate to generate a single mortality estimate for the combined drug 
users.  
     Deaths among illicit drug users are problematic to the society when they occur at young 
age because such deaths are premature and the society loses its potential workforce. Most 
of the existing studies have described mortality using traditional mortality indicators 
(death counts, CMRs, and SMRs), without considering the age at which the deaths 
occurred.  Only very few international studies, for example, Smyth et al. 2007 and 
Degenhardt et al. 2014, have explored the prematurity of deaths that occur among drug 
users in terms of PYLL. 
     The route of drug administration influences the health risks associated with drug use. 
Mortality among injectors has continued to receive research attention. Only very few 
studies have reported mortality among persons who snorted, smoked or orally ingested 
their drugs, in addition to injectors (Darke & Ross 2000; Thiblin et al. 2004; Quan et al. 
2007). Of these, none of them tested the association between the various routes of drug 
administration and all-cause deaths. 
     Mortality-related publications showing the causes of deaths from longitudinal cohort 
studies involving drug users in contact with drug treatment services during the last 10 
years have been summarised in Table 1.  
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3 Aims of the study 
 
The purpose of this study was to assess deaths that occurred among treatment-seeking 
illicit drug users during 1997–2010 time periods. The specific research objectives were: 
 
1. To examine the socio-demographic characteristics and drug abuse patterns of the 
clients at baseline (I). 
 
2. To assess all-cause and specific causes of deaths during the follow-up period (II). 
 
3. To evaluate the prematurity of deaths in the cohort in terms of potential years of life 
lost before 70 years (III). 
 
4. To examine the association between the route of drug administration and all-cause 
deaths (IV). 
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4 Methods 
 
4.1 STUDY POPULATION 
 
This study was based on the epidemiological part of HUUTI consortium research project. 
HUUTI is an acronym for Huumehoitotietokanta (Finnish) meaning illicit drug users’ 
treatment database.  The HUUTI study was initiated to carry out a long-term study of a 
large cohort of treatment-seeking drug users. The study population consisted of all 
consecutive 4817 drug-using clients aged 11–65 years who sought treatment at the 
Helsinki Deaconess Institute (HDI); the HDI is a public utility foundation located in 
Helsinki that offers drug treatment to residents of Helsinki and surrounding 
municipalities that make up the Greater Helsinki area (about 1.3 million residents). The 
HDI offers outpatient and inpatient treatments, and services are rendered free to the 
clients but their municipalities pay the service fees. In this study, there was no 
randomisation or selection criteria – the medical records of all consecutive treatment-
seeking clients that visited HDI between 1997 and 2008 were analysed. Hence, there was 
no attrition. Treatment-seeking at HDI was based on client self-referral, referral from 
doctors or other treatment centres, and other various sources. The clients came from 
various municipalities located within the Greater Helsinki area including Helsinki, Espoo, 
Vantaa, Kerava, Kirkkonummi, Porvoo, Nurmijärvi, Järvenpää, Lohja, Hyvinkää, and 
Tuusula. The service where the clients sought treatment caters for illicit drug users but 
there were some clients (minors and multiple drug users) with alcohol and prescription 
medications contributing most to the reasons for seeking treatment. 
 
4.2 DATA COLLECTION 
 
The data was not originally collected for research purposes but as a part of the practice.  
Structured interviews were conducted at each client’s first visit as part of routine clinical 
procedures. The clinicians collected clients’ demographic information, self-reported 
history of drug use, and their social, medical, and psychiatric histories. Items on the data 
collection instrument were adapted from the European Addiction Severity Index 
(EuropASI), the Treatment Demand Indicator Protocol (TDI) and other questions relevant 
for evaluating treatment needs and clinical monitoring of clients. The EuropASI contains 
questions on drug use, employment/support, family/social history, psychiatric disorders, 
medical and legal issues (Blacken et al. 1994; McLellan et al. 1992). The TDI contains 
questions on treatment contact, socio-demographic information and drug use (Kokkevi et 
al. 1997; Simon et al. 1999; Stauffacher & Kokkevi 1999). 
 
4.3 LINKAGE TO REGISTER 
 
Clients’ data were linked with the Finnish national Cause of Death Register and they were 
followed-up from the day of their first visit (i.e. baseline) until death or 31 December 2010, 
whichever came first. There was no loss to follow-up in this cohort. Information on 
underlying causes of death was recorded based upon ICD-10 codes. The linkage was 
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performed by Statistics Finland and the data were anonymised to prevent identification of 
the deceased individuals. 
 
4.4 STATISTICAL ANALYSES 
 
Statistical analyses were carried out using Statistical Package for Social Sciences (SPSS) 
software for Windows versions 17 (for study I), 19 (for study II), and 21 (for studies III and 
IV). Descriptive statistics were presented as frequencies, proportions, means, standard 
deviation (SD), and range. Group differences in descriptive statistics were tested using 
Chi-square test for categorical variables. Apart from Chi-square test, Fisher’s exact test 
was also used in study IV when SPSS output showed that one or more cells had expected 
count less than five (Institute for Digital Research Education [IDRE] 2015). In multivariate 
analyses of the longitudinal data, Cox Proportional Hazards models were used. 
 
4.4.1 Study I: socio-demography and drug use patterns 
In study I, the baseline data (i.e. data provided at first visit) of the 4817 clients who 
attended HDI during 1997–2008 were analysed.  Socio-demographic characteristics of the 
entire cohort were described, and drug use patterns were analysed based upon gender 
and age-groups (≤14, 15–24, 25–34, 35–44, and ≥45 years). Group differences in the drug 
use patterns were tested using Chi-square test for categorical variables. 
 
4.4.2 Study II: all-cause and cause-specific deaths 
In study II, all deaths, specific causes of deaths, and trends in mortality during the follow-
up period of 1997–2010 were examined. The time at risk of death was defined as the first 
day of the first visit to HDI until death or 31 December 2010, whichever came first. Chi-
square test was used to compare the characteristics of clients who were deceased at the 
end of follow-up to those who were alive. Crude mortality rates (CMRs) by gender and 
age-group were calculated and findings were expressed per 100,000 person-years, with 
95% confidence intervals (CIs). Standardised mortality ratios (SMRs) with 95% CIs for all-
cause deaths by gender and age-group were estimated. Poisson (log-linear) regression 
analyses were separately done for gender and gender/age-group to estimate 
trends/changes in annual CMRs. Furthermore, causes of deaths were grouped into drug-
induced deaths (DID) and non-drug induced deaths (Non-DID) based upon Randall et 
al.’s classification (Randall et al. 2009). Following Page et al.’s taxonomy/classification of 
conditions (Page et al. 2006), the number of avoidable deaths was estimated; the intention 
was to provide a general overview of avoidable mortality and dichotomy into amenable 
and preventable subtypes was beyond the scope of current analysis. 
 
4.4.3 Study III: potential years of life lost before 70 years 
In study III, the prematurity of deaths that occurred in the cohort in terms of potential 
years of life lost (PYLL) was estimated, and prematurity was defined as death before 70 
years. All-cause and cause-specific PYLL by gender were estimated. Descriptive statistics 
were presented as frequency, proportion, mean, SD, and range. PYLL rates per 1000 
person-years were estimated. The causes of PYLL were ranked based upon their 
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percentage contributions to the total PYLL. In addition, PYLL by primary drug reported at 
baseline was also estimated and ranked. 
 
4.4.4 Study IV: association between route of drug administration and deaths 
In study IV, analysis was limited to a subset of the cohort who used opiates and stimulants 
as primary drug at baseline (n=2766), with primary drug defined as the drug causing the 
client the most problems. The reason was because only these two groups of drugs could be 
injected, smoked, snorted, and consumed by oral route. Chi-square test and Fisher’s exact 
test were used to test differences in the underlying causes of death by route of drug 
administration (ROA). Cox proportional hazards regression models were used to analyse 
the association between ROA and all-cause deaths. In the Cox models, the outcome 
variable was all-cause death and the exposure variable was ROA. Potential confounders 
were sequentially introduced into the models and they included baseline variables such as 
gender (male vs. female), housing status (homeless vs. not homeless), number of drugs 
(multiple vs. single drug), type of primary drug (stimulants vs. opiates), past month 
frequency of using primary drug (no use, ≤once/week, 2-6 times/week, and ≥7times/week), 
and psychiatric comorbidities such as psychotic symptoms, depressive symptoms, suicidal 
thoughts, and suicide attempts (present, absent, missing data).  Results were presented as 
hazard ratios (HRs) and adjusted HR (aHRs) with 95% CIs, and statistically significant p-
value was set at ≤0.05. 
 
4.4.5 Missing data 
Being that the clients’ data were collected as part of routine clinical procedure, some of the 
variables had missing data. This was handled using complete case analysis, whereby 
responses to variables of interested were analysed using the number of clients with 
complete information as the denominator. Complete case analysis was chosen because 
some of the missing data were quite sizeable (>20%) and the use of imputation method 
would have diluted the data. In study IV, the psychiatric variables had extremely large 
amounts of missing data which would have reduced the power of the Cox regression 
models to detect any effect of these variables on the relationship between ROA and all-
cause deaths. Consequently, the missing data were re-coded as a separate category 
thereby increasing the responses for each psychiatric variable from two categories (i.e. 
present versus absent) to three categories (i.e. present versus absent versus missing data). 
ROA for 127 clients was missing, and they were grouped as a separate category 
“unspecified ROA” in order to identify the distribution of all the deaths. 
 
4.5 ETHICAL CONSIDERATIONS 
 
Ethical approvals for the HUUTI study were obtained from the Research Ethics 
Committee of the Hospital District of North-Savo and the Ethics Committee of HDI. 
Permissions were obtained from the Ministry of Social Affairs and Health of Finland and 
from appropriate municipal authorities of all Greater Helsinki area communities where 
clients resided. Informed consent from the clients was not required because none of them 
was contacted for the study itself. 
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5 Results 
 
 
5.1 SOCIO-DEMOGRAPHIC CHARACTERISTICS AND DRUG USE 
PATTERNS AT BASELINE 
 
A total of 4817 clients attended HDI during 1997–2008. The mean age was 24.5 years; over 
half of them (56%) were in the 15–24 years age-group while only 2% were aged ≥45 years 
(Table 2). 
 
Table 2. Socio-demographic characteristics of the clients at baseline (i.e. first visit)  
Variable             n (%) 
Age in years (n = 4817)  
    ≤ 14            159 (3) 
    15–24           2685 (56) 
    25–34           1367 (29) 
    35–44             489 (10) 
    ≥ 45            117 (2) 
Gender (n = 4817)  
    Male            3365 (70) 
    Female          1452 (30) 
Marital status (n = 3784)  
    Married or cohabiting             299 (8) 
    Unmarried‡          3485 (92) 
Homeless  (n = 4616)§  
    Yes           1020 (22) 
    No           3596 (78) 
Education (n = 2447)           
    Elementary school          1846 (75) 
    High school or vocational school            488 (20) 
    University              43 (2) 
    Other              70 (3) 
Employment status (n = 2481)  
    Employed             333 (13) 
    Unemployed          1406 (57) 
    Students            489 (20) 
    Other            253 (10) 
Home municipality (n = 4788)  
    Helsinki          3357 (70) 
    Outside Helsinki¶          1431 (30) 
Nationality (n = 4798)  
    Finnish                                                                                                                           4682 (98)
    OthersŦ            116 (2) 
‡Include unmarried, separated/divorced or widowed. §Presence or absence of postal code or address. 
¶Espoo, Vantaa, and other municipalities within Greater Helsinki area. ŦSwedish, Russian, Estonian, 
Vietnamese, Somalian, and others. Different denominators (n) due to missing data.  
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     Almost all of them (98%) were of Finnish nationality; they were mostly males (70%), 
unmarried (92%) and 70% of them were from Helsinki municipality. Educational levels 
were low and three-quarters (75%) had elementary education. More than half (57%) were 
unemployed and nearly one-quarter (22%) were considered homeless (Table 2). 
     The various drugs consumed by the clients were categorised as alcohol, cannabis, 
prescription medicines, opiates (this refers to all opiate/opioid-related drugs), stimulants, 
and other drugs (Table 3). Prescription medicines were mainly benzodiazepines used for 
non-medical purposes. Buprenorphine, followed by heroin, was the most common drug 
within the opiates class while amphetamines were the predominant drug within the 
stimulants class. The distributions of the primary and secondary drugs of abuse are 
presented in Figure 8. Generally, opiates (n=1432) were the most common primary drugs, 
followed closely by stimulants (n=1334) (Figure 8).  
 
 
Table 3. Classification of the various drugs used by the clients 
 
Drug classes Components 
 
 
Alcohol 
 
beer, wine, spirits 
  
Prescription medicines mainly benzodiazepines used for non-medical purposes, such as diazepam, 
lorazepam, oxazepam, temazepam, triazolam, alprazolam, chlordiazepoxide 
  
Cannabis marijuana, hashish, hashish oil 
  
  
Opiates* heroin, buprenorphine, methadone, dextropropoxyphene, ethylmorphine, 
oxycodone, opium, morphine, codeine phosphate, dihydrocodeine, 
pentazocine, codeine-containing cough medicines 
  
Stimulants cocaine, amphetamine, methamphetamine, dexamphetamine, ecstasy 
(MDMA), methylphenidate, phenmetrazine, ephedrine/ 
norephedrine/pseudoephedrine 
  
Others hallucinogens (lysergic acid diethylamide, psilocybin mushrooms, 
unspecified mushrooms), solvents/inhalants (butane, kerosene, unspecified 
solvents), gamma-butyrolactone, gamma-hydroxybutyric acid, and anabolic 
steroids 
 
* In the dataset used for this study, all opiate/opioid drugs were grouped/coded as “opiates”. Consequently, 
the term “opiates” was used in the results/discussion/conclusion/recommendation sections.  
MDMA  means 3, 4-methylenedioxy-methamphetamine. 
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Figure 8. Primary and secondary drugs report at initial visit. 
 
 
     Primary drugs were mainly administered intravenously (45%), and used daily (44%) 
during the past month. In terms of gender and age-group, the use of opiates as primary 
drug was more common among men (32%) while stimulant use was more common among 
women (31%, P<0.001). Clients in the oldest age-group, ≥45 years, used both opiates and 
stimulants in equal proportions (33% respectively) while more than half (59%) of those in 
the youngest age-group, ≤14 years, used alcohol as primary drug (P< 0.001). Intravenous 
(I.V.) administration of primary drug was high in both genders relative to the other ROA 
(P<0.001), and was also high in all the age-groups except those aged ≤14 years who mainly 
consumed their primary drug orally (P<0.001). Daily use of primary drug during the past 
month was common in both genders compared to the other frequencies of use (P<0.001), 
and the same was true for all the age-groups except those aged ≤14 years who mainly used 
theirs ≤once/week (P<0.001). 
     Overall, cannabis was the most common secondary drug with 1627 users (Figure 8). A 
higher proportion of the clients smoked their secondary drug (39%), and used it 
≤once/week during the past month. There was no gender difference in terms of secondary 
drug (P=0.34) but ≤14 years age-group had higher proportions of clients who used 
cannabis as a secondary drug than the other age-groups (P<0.001). Smoking of the 
secondary drug was similar in both genders (P=0.61) while oral consumption was more 
common among 25–34, 35–44, and ≥45 years age-groups (P<0.001). A higher proportion of 
women than men (P<0.001) and clients aged ≤14 years than other age-groups (P<0.001) 
used their secondary drug ≤once/week during the past month. Primary drug subgroups 
by route of administration are summarised in Table 4, with I.V. use being more common 
among opiate and stimulant users. Surprisingly, a few of those who reported alcohol as 
their primary drug consumed it through unusual routes such as I.V., smoking, and 
snorting. 
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36 
 
 
 
Table 4. Primary drug reported by 4817 clients at initial visit by routes of administration 
 
                                 Routes of administration of primary drug 
Primary drug¶ Intravenous 
        n (%) 
    Smoking 
       n (%) 
         Oral 
         n (%) 
  Snorting 
      n (%) 
Missing data* 
          n  
      
    Alcohol         2 (0.1)      3 (0.3)     813 (69.5)      1 (0.4)        185 
    Cannabis         0 (0)  800 (83.7)         7 (0.6)      0 (0.0)          87 
Prescription medicines‡         4 (0.2)       1 (0.1)       75 (6.4)      1 (0.4)          15 
    Opiates  1068 (53.6)  147 (15.4)       69 (5.9)    88 (31.4)          60 
    Stimulants    908 (45.6)      5 (0.5)     166 (14.2)  188 (67.1)          67 
    Others      11 (0.6)      0 (0.0)       39 (3.3)       2 (0.7)            5 
    Total  1993 (100.0)  956 (100.0)   1169 (100.0)  280 (100.0)        419 
* Data on route of administration of primary drug for 419 clients were not available in the database. 
 ¶Primary drug defined as the drug that causes client the most problem. ‡Mainly benzodiazepines. 
 
 
     The use of multiple drugs (i.e. use of two or more drugs) was extremely high in the 
cohort and the proportion of any multiple drug use was 91%. This was slightly higher in 
males (92%) than in females (89%, P=0.003). The proportion of multiple drug users was 
highest in the 25–34 years age-group (96%) and lowest in the ≤14 years age-group (55%, 
P<0.001). The primary drug and secondary drug combinations are presented in Table 5. 
Almost three-quarters of primary alcohol users mentioned cannabis as a secondary drug, 
and half of primary cannabis users mentioned alcohol as a secondary drug. Nearly 30% of 
primary prescription medicine users combined it with alcohol, 26.2% of primary opiate 
users combined it with prescription medicine while 45.3% of primary stimulant users 
combine it with cannabis. 
     The number of clients seeking treatment progressively declined after 2000. The most 
frequent illicit drug reported as primary drug changed from stimulants to opiates after 
2002 but cannabis remained the most frequently reported secondary drug during 1997-
2008. 
 
Table 5. Primary drugs and secondary combinations reported by the clients at initial visit 
 
                                                 Primary drug¶  
Secondary drug  Alcohol 
   n (%) 
   Cannabis 
       n (%) 
Prescription  
  medicines‡ 
         n (%) 
  Opiates 
      n (%) 
Stimulants 
     n (%) 
   Others 
    n (%) 
       
Alcohol   13 (1.6)  398 (50.5)   26 (28.3)       91 (6.8)     252 (20.2)  10 (19.2) 
Cannabis 606 (74.0)    81 (10.3)   12 (13.0)     344 (25.6)     565 (45.3)  19 (36.5) 
Prescription medicines‡   57 (7.0)    31 (3.9)   23 (25.0)     353 (26.2)     133 (10.7)    4 (7.7) 
Opiates   22 (2.7)    48 (6.1)   14 (15.2)     239 (17.8)     177 (14.2)    4 (7.7) 
Stimulants 100 (12.2)  214 (27.2)   16 (17.4)     302 (22.4)     104 (8.3)  13 (25.0) 
Others   21 (2.6)    16 (2.0)     1 (1.1)      17 (1.3)      16 (1.3)    2 (3.8) 
Total 819 (100.0)  788 (100.0)   92 (100.0) 1346 (100.0) 1247 (100.0)  52 (100.0) 
(Missing data)* 185  106     4     86     87    5 
* Data about secondary drug for 473 clients were not available in the database (possibly including those clients who did  
not have any secondary drug).‡Mainly benzodiazepines. ¶Primary drug – the drug causing client the most problem. 
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5.2 ALL-CAUSE AND CAUSE-SPECIFIC DEATHS 
 
The clients were followed-up for between 0.01–13.9 years, with mean follow-up period of 
8.6 years, and they contributed 41567.5 person-years. Out of the 4817 clients, 496 (10.3%) 
died at the end of the follow-up in 2010, at the mean age of 33.8 years (SD=10.2, range: 16–
68 years). At 417 deaths, male clients had higher number of death than females, while 
clients aged 25–34 years had more number of deaths (n=189) than the other age-groups. 
Since there was no death among clients aged 14 years or younger, the 15–24 years age-
group became the youngest age-group for mortality data. The overall CMR was 1193.2 per 
100,000 person-years and the overall SMR was 8.9 (95%CI: 8.1–9.7). CMRs were higher 
among male clients than females, and highest among the oldest age-group (i.e. those aged 
≥45 years) in both genders.  Overall SMR was higher in females (11.7, 95%CI: 9.3–14.6) 
than male clients (8.5, 95%CI: 7.7–9.3), and the youngest age-group (i.e. those aged 15–24 
years) had the highest SMRs in both genders. Based on yearly findings, the overall CMR 
declined from 2054.7/100,000 in 1997 to 1017.7/100,000 in 2010, and the overall average 
annual percent change for all-cause mortality for the 1997–2010 period was approximately 
–4% (P=0.01). Most of the deaths (n=322) were from external causes while the remaining 
174 deaths were from disease-related causes. Based upon the ICD-10 code combinations 
recommended by Randall et al. (2009), 225 out of the 496 deaths (45.4%) were drug-
induced deaths (DID) while 271 (54.6%) were non-drug induced deaths (Non-DID). The 
individual specific causes of the 496 deaths are shown in Table 6. 
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Table 6. Causes of deaths during 1997–2010 (N=496) 
Causes of deaths 
 
Number 
1) Disease-related (N=174)  
  
Infectious diseases  (A00–B99, J65)      16 
     HIV/AIDS         9 
     Hepatitis        4 
     Others         3 
Malignant neoplasms  (C00–C97)       15 
Endocrine, nutritional and metabolic diseases (E00–E90)        4 
Mental and behavioural disorders (F00–F99)      49 
     Due to use of opioids       12 
     Due to multiple drug use       27 
     Others      10 
Diseases of the nervous system (G00–G99)        5 
Diseases of the circulatory system (I00–I425, I427–199)      45 
     Ischaemic heart diseases       12 
     Cerebrovascular diseases         8 
     Other heart diseases       24 
     Others diseases         1 
Diseases of the respiratory system (J00–J64, J66–J99)      10 
     Pneumonia         8 
     Others         2 
Diseases of the digestive system  (K00–K39)      18 
     Alcoholic liver disease       14 
     Others         4 
Ill-defined/unknown (R96–R99)      12 
  
2) External causes (N=322)  
  
Transport accidents  (V01–V99)       16 
     Land traffic accidents       15 
     Water transport accidents          1 
Accidental falls (W00 –W19)         2 
Mechanical forces, accidental drowning, electrocution, asphyxia (W20, W70, W78, W85–W99)          7 
Exposure to smoke, heat, cold (X00, X09, X11, X31)          5 
Accidental poisoning/overdose (X40–X49)     165 
     By antiepileptics, sedative/hypnotics, other psychotropic drugs       30 
     By narcotic and psychodysleptics     110 
     By alcohol        18 
     Others          7 
Suicide/intentional self-harm (X60–X84)     108 
     By antiepileptics, sedative/hypnotics, other psychotropic drugs       23 
     By narcotics and psychodysleptics          9 
     By hanging/strangulation       40 
     By Jumping from a height       13 
     By a moving object          6 
     Others        17 
Assault (X85–Y09)       14 
     By sharp object        10 
     Others          4 
Undetermined / sequelae of external cause (Y16–Y84, Y87–Y89)         5 
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Table 7. Avoidable deaths among the 496 deaths based upon Page et al. (2006) taxonomy of 
avoidable mortality 
 
Major condition group/cause ICD-10 code         Number 
Infections              
   Selected invasive bacterial and protozoal infections A39, A41, J15, J18            10 
   Hepatitis B18              4 
   HIV/AIDS B20-B24              9 
   
Malignant neoplasms (cancer)              
   Nasopharynx C11              1 
   Oesopharynx C15              1 
   Stomach C16              1 
   Liver  C22              3 
   Lung C34              2 
   Breast C50              2 
   
Nutritional, endocrine, and metabolic conditions                
   Diabetes E10-E14              4 
   
Drug use disorders             
   Alcohol related disease F10, I42.6, K70            21 
   Illicit drug use disorders F11-F15, F19            44 
   
Neurological disorders   
   Epilepsy G40, G41              3 
   
Cardiovascular disorders              
   Ischaemic heart disease I21, I25            12 
   Cerebrovacular diseases I60, I61, I69              8 
   
Respiratory diseases                
   Pulmonary embolism I26              1 
   Chronic obstructive pulmonary disease J44              1 
   
Digestive disorders                
   Appendicitis, pancreatitis K35, K86              2 
   Chronic liver disease K73, K74              2 
   
Unintentional injuries            
   Road traffic injuries V03, V06, V09-V80             13 
   Falls W01              2 
   Fires, burns X00, X09              3 
   Accidental poisonings (overdose) X40-X49          165 
   Drowning W70              3 
   
Intentional injuries            
   Suicide and self-inflicted injuries X60-X82          108 
   Violence (assault) X91, X99, Y00, Y09            14 
 
Total avoidable deaths -          439 
Percentage of all deaths -      439/496 (88.5%) 
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     Accidental poisoning/overdose was the single most important cause of deaths (n=165) 
while suicide was the second most important cause, with a total of 108 deaths. Mental and 
behavioural disorders (n=49) and circulatory system diseases (n=45) were the third and 
fourth leading causes of deaths respectively. Deaths in this cohort were further classified 
based upon Page et al. (2006) taxonomy of avoidable mortality.  As presented in Table 7, 
the majority of the deaths (n=439, 88.5%) were avoidable. Unintentional injuries 
contributed the most to these avoidable deaths (n=186), and this was driven by a high 
number of deaths from accidental overdose (Table 7). Intentional injuries (n=122) also 
made major contributions to avoidable deaths, principally due to suicide and self-inflicted 
injuries. Deaths from cancers like non-follicular lymphoma and monocytic leukemia, and 
other causes of death whose ICD-10 codes were not included in Page et al. (2006) 
taxonomy of avoidable mortality were considered to be unavoidable deaths. 
     Generally, the proportions of disease-related deaths were higher in female clients, while 
deaths from external causes were higher in male clients. Older clients (≥45years) died 
more from disease-related causes like malignant neoplasm and circulatory system disease 
while younger clients died more from external causes like accidental overdose and suicide. 
Based upon primary drugs reported at baseline, 188 deaths occurred among stimulants 
users and 142 among opiates users.  
 
5.3 POTENTIAL YEARS OF LIFE LOST BEFORE 70 YEARS 
 
The 496 deceased clients potentially lost a total of 17951 life years (14898 among males and 
3053 among females) before 70 years. The overall average (mean) PYLL per deceased 
client was 36.2 years, and the overall PYLL rate was 431.9 per 1000 person-years. The 
PYLL rate among male clients (513.0/1000 person-years) was more than double that of 
females (243.7/1000 person-years). However, the mean PYLL per deceased client was 
higher among females (38.6 years) than males (35.7 years). The leading causes of PYLL are 
presented in Table 8. The two top-ranking contributors to the total PYLL were accidental 
overdose (34.8%), and suicide (24.0%). Overall, clients who reported stimulants as their 
primary drug at baseline contributed the most to the total PYLL followed by opiate users 
but cannabis users had the highest mean PYLL relative to others (Table 8). 
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Table 8. Potential years of life lost (PYLL) before 70 years by leading causes of death and 
primary drugs reported at baseline, 1997–2010 
 
Variable Number 
of deaths 
    PYLL   % of total   
     PYLL     
      Mean         
      PYLL 
      PYLL per  
      1000 PY     
Leading causes of deaths      
   Total deaths      496    17951     100.0        36.2           431.9 
   Accidental overdose     165       6252       34.8        37.9           150.4 
   Suicide     108       4312       24.0        39.9           103.7 
   Mental & behavioral disorders       49       1907       10.6        38.9             45.9 
   Circulatory system diseases       45       1249         7.0        27.8             30.0 
   Traffic accidents        15         539         3.0        35.9             13.0 
   Malignant neoplasms       15         297         1.7        19.8               7.1 
   Assault       14         580         3.2        41.4             14.0 
      
Primary drugs at baseline       
   Total deaths      496    17951     100.0        36.2           431.9 
   Stimulants     188      6347       35.4        33.8           152.7 
   Opiates     142      5343       29.8        37.6           128.5 
   Alcohol       74      2507       14.0        33.9             60.3 
   Cannabis        69      2938       16.4        42.6             70.7 
   Prescription medicines       17        629         3.5        37.0             15.1 
   Others         6        187         1.0        31.2               4.5 
 
PY = person-years. PYLL rate per 1,000 person-years = PYLL ÷ number of person-years contributed by clients 
aged less than 70 years multiplied by 1000. 
 
 
5.4 ASSOCIATION BETWEEN ROUTE OF DRUG ADMINISTRATION AND 
ALL-CAUSE DEATHS 
 
The results reported here were based upon study IV. Data analysis on the association 
between route of administration and all-cause deaths was restricted to only clients who 
reported opiates and stimulants as their primary drug at initial visit.  Out of a total of 2766 
clients who reported opiate and stimulant use at baseline interview, 330 (11.9%) were 
deceased at the end of the follow-up period. Of these, 142 deaths occurred among clients 
who reported opiate use at baseline interview (9.9%, n=142/1432) and 188 deaths among 
stimulant users (14.1%, n=188/1334). There were statistically significant differences in the 
proportions of all-cause deaths by ROA reported at baseline interview (P=0.012). The 
proportion was 12.7% (n=251/1976) among I.V. drug users, 11.5% (n=27/235) among oral 
users, 7.9% (n=12/152) among smokers, 6.9% (n=19/276) among snorters, and 16.5% 
(n=21/127) among those with missing data (i.e. unspecified ROA). 
     The results of Cox regression analyses are shown in Table 9. There was an association 
between ROA and all-cause deaths. In the univariate model (i.e. model 1), the hazard (or 
risk) for all-cause death was statistically significantly reduced among smokers (HR: 0.50, 
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95% CI: 0.28–0.90, P=0.021) and snorters (HR: 0.56, 95% CI: 0.35–0.89, P=0.014) in 
comparison to I.V. users. The hazards among oral users (HR: 0.92, 95% CI: 0.62–1.37, 
P=0.682) and those with unspecified ROA (HR: 1.23, 95% CI: 0.79–1.92, P=0.358) were not 
statistically significantly different from I.V. users. In the final multivariate model (i.e. 
model 4), only the reduction in the risk of all-cause deaths among smokers compared to 
I.V. users remained statistically significant (aHR: 0.52, 95% CI: 0.28–0.97, P=0.039) after 
adjusting for gender, homelessness, drug use behaviours, and psychiatric comorbidities 
present at baseline interview. 
  
Table 9. Cox regression analyses of the association between the routes of administration of 
the primary drug at baseline (opiates and stimulants) and all-cause deaths, adjusted for 
potential cofounders 
 
Route of 
administration 
     Model 1 
  HR (95% CI) 
        Model 2 
    aHR (95% CI) 
         Model 3 
     aHR (95% CI) 
     Model 4 
   aHR (95% CI) 
 Intravenous 1.00 (reference)   1.00 (reference)    1.00 (reference)     1.00 (reference) 
 Smoking 0.50 (0.28–0.90)‡   0.47 (0.26–0.87)‡    0.59 (0.32–1.09)     0.52 (0.28–0.97)‡ 
 Oral 0.92 (0.62–1.37)  0.90 (0.59–1.37)    0.91 (0.59–1.41)     0.92 (0.60–1.43) 
 Snorting 0.56 (0.35–0.89)‡  0.63 (0.39–1.01)    0.65 (0.41–1.05)     0.69 (0.43–1.11) 
 Unspecified     1.23 (0.79–1.92)  1.32 (0.81–2.17)    1.49 (0.73–3.04)     1.47 (0.72–3.00) 
 
Model 1 – univariate model containing only the main predictor (route of administration of primary drug).   
Model 2 – adjusted for gender (male vs. female) and homelessness (yes vs. no).  
Model 3 – adjusted for model 2 plus drug use behaviours (number of drug [multiple vs. single drug], type of 
primary drug [stimulants vs. opiates], past month frequency of using primary drug [no use, ≤once/week,  
2-6 times/week, ≥7 times/week]).  
Model 4 – full model - adjusted for model 3 plus psychiatric comorbidities (psychotic symptoms, depressive 
symptoms, suicidal thoughts, and suicide attempts [present, absent, missing data]).  
HR – hazard ratio.  
aHR – adjusted HR.  
CI – confidence interval.   
‡Statistically significant at P≤0.05.   
Analysis restricted to only 2766 clients who reported opiates (n=1432) and stimulants (n=1334) as primary 
drug at initial visit. 
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6 Discussion 
 
 
6.1 MAIN FINDINGS  
 
6.1.1 Characteristics of the cohort at baseline  
Study I showed that the number of male treatment-seekers were more than twice that of 
females. This finding was compatible with the existing literature whereby female drug 
users in treatment tended to be fewer than male drug users (Demirci et al. 2015; 
Selemogwe et al. 2014; Wong & Barnett 2010; Strike et al. 2003). National report on Finnish 
drug situation had similarly shown that the majority of drug users attending treatment 
were men (Varjonen 2015; Forsell & Nurmi 2015). Although the prevalence of substance 
use disorders in general is lower among women compared to men, evidence from 
international settings has highlighted concerns about treatment barriers for women. A 
qualitative study conducted in Northern California among 36 women drug users 
identified fear of punitive actions (e.g. losing child custody) and stigma as some of the 
factors that prevent female drug abusers from seeking treatment (Jessup et al. 2003). 
Further investigation is necessary to ascertain if female drug users in Finland are facing 
any gender-specific barriers to treatment participation. This is particularly important since 
a recent report based upon a subset of this HUUTI cohort showed that treatment-seeking 
males were more than females in each year, and also showed a decline in treatment 
seeking after 2006 among women drug users with children (Basnet 2014; Basnet et al. 
2015).  
     In this cohort, older drug-using clients (≥45 years) were just 2% of the total treatment 
seekers. Treatment data from Finland (Varjonen 2015; Forsell & Nurmi 2015) also showed 
fewer older treatment-seekers relative to younger ones. It seems that younger drug users 
seek treatment more readily than their older counterparts. It could also mean that there are 
less older people in the general Finnish population using drugs: for example, there was 
nobody in the 60–69 age group in the 1992–2002 general population drug survey in 
Finland (Hakkarainen & Metso 2003), and a more recent publication reported few persons 
in 45–69 age group (Hakkarainen et al. 2015).  However, these findings should be 
interpreted in view of the fact that drug use in older adults could be underreported due to 
shame and stigma associated with drug use, confusing drug use with other medical 
conditions, and lack of appropriate screening tools for identifying drug use in older adults 
(Rosen et al. 2013). Using data from the National Household Survey on Drug Abuse, 
researchers in the United States of America have estimated that the number of older adults 
in need of substance abuse treatment will increase from 1.7 million in 2000 and 2001 to 4.4 
million in 2020 (Gfroerer et al. 2003). Similar increase is expected in Europe and it could be 
explained by ageing population in many countries and ageing of drug users (Beynon 2009; 
EMCDDA 2010b). A qualitative study conducted among older drug users in contact with 
drug treatment services in Merseyside, United Kingdom revealed that they experienced 
high levels of physical and mental morbidities, and some older drug users complained 
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about being treated poorly/differently by healthcare staff (Beynon et al. 2009). In another 
UK study, researchers identified that not wishing to be around younger drug users was a 
major barrier to attending treatment among older drug users (Ayres et al. 2012). It is not 
known if older drug users in Finland experience any barriers to treatment, and Rosen et al. 
(2013) have drawn attention to the paucity of research in this area.  
     Opiates and stimulants were the two most important primary drugs contributing to 
treatment-seeking in this cohort. Clients exhibited severe patterns of drug use, 
characterised by high proportions of multiple drug use, I.V. administration of primary 
drug, and daily consumption of primary drug during the past month, which was 
compatible with previously reported data in Finland (Varjonen 2015; Forsell & Nurmi 
2015). There could be several explanations for these drug use patterns. The use of multiple 
drugs may arise from the drug user’s desire to achieve an effect not attainable with only 
one drug (Kedia et al. 2007), to increase the effect of another drug or to reduce the negative 
effects of drugs (Boys et al. 2001). Clients might have chosen I.V. administration because it 
provided the fastest speed of absorption compared to other routes (EMCDDA 2010a), 
thereby enabling the drug user to experience immediate euphoric effect of the drug. Daily 
use of drug during past month is indicative of a subgroup with severe drug problems.  
     Surprisingly, few clients consumed alcohol through unusual routes; intake via I.V. 
route, smoking, and snorting have been reported in a case study by UK researchers 
(Mahdi & McBride 1999) and in various international news media (British Broadcasting 
Corporation [BBC] 2006; Evening Standard 2012; Castillo 2013). The three persons in the 
case study mainly injected vodka and the reasons for doing so included rapid onset of 
effect, pleasure from injecting, and avoiding detection of alcohol smell on the breath 
(Mahdi & McBride 1999). Inhaling/smoking alcohol vapour, and snorting alcohol (e.g. 
vodka) through a straw or from a thin glass tube were some of the unusual routes of 
alcohol intake (BBC 2006; Evening Standard 2012; Castillo 2013). It is possible that persons 
using alcohol through unusual routes were so few that this topic failed to stimulate 
enough scientific research publications. 
     Taken together, these risky consumption patterns have negative consequences on the 
health of drug users. Combinations of certain drugs (for example, opiates and alcohol or 
opiates and benzodiazepines) raise the risk of accidental overdose (Gossop et al. 2002) 
because of respiratory depression from central nervous system drug interactions (Warner–
Smith et al. 2001b). Injectors are predisposed to contracting or transmitting blood-borne 
viral infections, such as hepatitis and HIV, through sharing of contaminated injecting 
equipment (Trisler et al. 1999; Mathers et al. 2008; Loebstein et al. 2008). Furthermore, I.V. 
drug administration permits large amounts of drugs to be delivered directly into the blood 
stream, and they rapidly get into the brain thereby predisposing to overdose (EMCDDA 
2010a). Hence, deaths through overdose are common among injectors (Mathers et al. 2013; 
Colon et al. 2006). High-risk behaviours of injecting, smoking and snorting alcohol could 
lead to nose damage, overdose, and brain damage (BBC 2006; Evening Standard 2012; 
Castillo 2013). 
     This study showed that the number of clients seeking treatment at HDI generally 
declined after 2000. This coincided with the relocation of the substance abuse unit of HDI 
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to another area of Helsinki in 2000 which was a far distance from the previous location. It 
could be inferred that this relocation might have impacted negatively on drug users who 
could not afford to travel to the new location. Another possible explanation for this decline 
in treatment seeking could be lack of awareness about the new location. Certain 
subgroups of drug users appeared to have been more affected by the relocation. To 
provide more contexts on the two locations, many amphetamine users lived in the old 
location while much younger persons who mostly used opiates lived in the new location. 
Therefore, the decrease in the number of clients reporting stimulants as their primary drug 
after 2002 was not too surprising. Rather, it highlighted the possibility that many stimulant 
users living in the old location might have unmet needs for drug treatment. Given the 
global economic downturn, it is not known if the decline is related to reduced economic 
resources in the municipalities, which has been reported to interfere with access to some 
drug services (Simojoki 2013). On the other hand, there was a similar trend at the national 
level whereby the percentage of opiate users among treatment-seekers has increased 
significantly since the 2000s (Varjonen 2015; Forsell & Nurmi 2015). 
     In comparison to the local situation, drug use patterns in this cohort were similar to 
those reported in Finland in terms of preponderance of males and clients from Helsinki, 
social disadvantage (such as low educational level, homelessness, and unemployment), 
and high levels of I.V. drug use and multiple drug use (Varjonen 2015; Forsell & Nurmi 
2015; Hakkarainen et al. 2011; Tammi et al. 2011; Alho et al. 2007). As reported in other 
data from Finland, there were more opiate users than other primary drug subgroups. 
However, unlike other Finnish data, primary opiate and stimulant users were nearly equal 
in this cohort (30%, n=1432/4817 versus 28%, n=1334/4817 respectively). Clients in this 
cohort were younger (mean age of 24.5 years) than those in the treatment data reported by 
Varjonen 2015 (mean age of 31 years) and the mean age of 29 years reported by Tammi et 
al. 2011. At 22%, the proportion of homeless persons in this cohort exceeded 9–10% 
reported by Varjonen 2015 and Forsell & Nurmi 2015 which suggested a greater degree of 
social disadvantage in this study cohort. 
 
6.1.2 Deaths that occurred during the follow-up period 
A total of 496 clients died, and their deaths exceeded those of their peers in the general 
Finnish population of the same gender and age-groups. In study II, the findings that the 
majority of deaths occurred in male drug users and that clients died in their mid-thirties 
were comparable to previous report about drug-related mortality in Europe (Giraudon et 
al. 2012). However, the average age at death in this study was younger than late-forties 
reported among Swedish drug users (Stenbacka et al. 2010) which is possibly due to 
differences in the study populations, for example, the Swedish cohort had very few people 
younger than 15 or older than 55 years. At SMR of 8.9, the overall excess mortality in this 
cohort was higher than 5.94 reported by Nyhlén et al. (2011) for Swedish drug users and 
4.8–6.4 across different eras reported by Merrall et al. (2012) for Scottish drug users. A 
possible explanation for this higher SMR is that, unlike the Swedish and Scottish studies, 
this cohort had a high proportion of other adverse conditions such as homelessness which 
worsens health problems; a 5-year study of two fixed cohorts in Scotland demonstrated 
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that patients admitted for drug-related conditions had a further 7-fold risk of mortality if 
they were homeless (Morrison 2009). As with gender-specific patterns of excess mortality 
reported in Amsterdam, Barcelona, Denmark, Dublin, Lisbon, London, Rome and Vienna 
(Bargagli et al. 2006), the overall SMR among female drug users in this cohort exceeded 
that of males. This higher SMR in females reflects lower mortality among females in the 
general population (Darke et al. 2007). 
     Despite fluctuations across the years, the cohort’s mortality rate declined at the end of 
2010. This finding suggested important progress in terms of drug abuse treatment in 
Finland. Apart from the organisation and delivery of drug treatment services at 
municipality level which brings services closer to Finnish drug users, another explanation 
for declining mortality rate could be drug policy shift in Finland beginning from 1997, 
which marked the introduction of opioid substitution treatment (Selin et al. 2013) and 
possibly reduced deaths among opiate users. However, the overall average annual percent 
change for all-cause mortality was not huge (–4%) and the CMR for the cohort was above 
the European Union average in 2009 which was 21/1,000,000 population aged 15–64 years 
(EMCDDA 2011b). This study highlighted a need for more efforts to reduce deaths among 
drug users. 
     Deaths from accidental overdose, followed by suicide, far outnumbered the other 
individual causes of deaths. The preponderance of accidental overdose deaths 
corroborated findings from other studies among drug users in other Nordic countries 
(Clausen et al. 2009; Fugelstad et al. 2014; Ødegård et al. 2007; Ravndal et al. 2015; Ravndal 
& Amundsen 2010). Given that there were a high proportion of I.V. drug users in this 
cohort, large amounts of drugs were probably delivered directly into the blood stream 
thereby causing untimely deaths. Since multiple drug use was also high in this cohort, 
respiratory depression from central nervous system drug interactions (Warner–Smith et al. 
2001b), could be a possible explanation for these accidental overdose deaths; for example, 
combination of opiates and benzodiazepines or opiates and alcohol. Previous research has 
suggested that these two leading causes of deaths may share some relationships. 
According to Bohnert et al. (2010), overdose is a common suicide method, and drug users 
who have experienced overdose and suicide attempt share common risk factor such as 
severe drug-related problems. It is also possible that some of the accidental overdoses 
could actually be suicides since a previous study conducted in the UK found that 49% of 
the illicit drug users overdosed with suicidal intent (Neale 2000). This information is very 
important in terms of prevention and intervention. 
     Other important individual causes of deaths were mental and behavioural disorders 
(mainly due to multiple drug use) and diseases of the circulatory system (mainly from 
ischaemic heart diseases and other heart diseases). It is noteworthy that there were very 
few deaths from blood-borne viral infectious diseases like HIV and hepatitis despite the 
high proportion of I.V. drug users, which contradicted findings from other studies with 
high HIV and hepatitis deaths (Manfredi et al. 2006; Degenhardt et al. 2014). This could be 
partly explained by the low prevalence of infectious diseases in the general population of 
Finland; for example, the adult prevalence of HIV in Finland in 2011 was 0.1% (Avert 
2015). Other possible explanations for very few infectious disease deaths could be 
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increased intervention and prevention activities including education, and access to sterile 
injecting equipment following an outbreak of HIV among injecting drug users in Helsinki 
metropolitan area of Finland in the late 1990s (Kivelä et al. 2007). Since HIV and hepatitis 
run a chronic course, it could be argued that the follow-up period, with an average of 8.6 
years, was not long enough to track such deaths. 
     On further analyses of the causes of deaths, it was observed that there were more non-
DID in this cohort than DID, as reported elsewhere (Beynon & McVeigh 2007).  Older drug 
users in this cohort died more from non-DID such as circulatory system diseases and 
malignant neoplasms than younger drug users, which was in line with earlier reports of 
differences in the types of death affecting older and younger drug users   (Beynon et al. 
2010a; Stenbacka et al. 2010). Such chronic health conditions are common in old age but 
lifetime of drug use contributes to health harms in older persons (Boddiger 2008; White et 
al. 2011). DID seem to receive more attention possibly because such deaths are acute in 
nature and tend to disproportionately affect young persons; there is a need to extend 
similar attention to non-DID. This is particularly important given the high proportion of 
avoidable mortality in this present study. Similar to findings from a study of causes of 
deaths among 43789 Australian drug users (Degenhardt et al. 2014), nearly nine out of ten 
deaths in this cohort were potentially avoidable. Hence, there is a need for comprehensive 
preventive and intervention efforts that give attention to both DID and non-DID as they 
encompass deaths that are unnecessary and avoidable. 
     In comparison to previous reports/studies in Finland, results of this study were 
comparable to those from Karjalainen et al.’s study that was not exclusively focused on 
opioid users. Similar to their study (Karjalainen et al. 2010), excess risk of death in this 
cohort of treatment-seeking drug users was nearly 10 times that of the reference 
population. However, suicide was the most common cause of death in Karjalainen et al.’s 
study (over one-fifth of all deaths) while accidental overdose was the most common cause 
of death in this cohort (one-third of all deaths). Apart from differences in the study 
population, this disparity in the leading cause of death might be explained by seemingly 
high level of mental health problems among the drugged drivers in Karjalainen et al.’s 
cohort. In terms of avoidable mortality, findings from this study could not be compared to 
any similar data from Finland. To the best of my knowledge, there is no locally available 
study on avoidable mortality among drug users in Finland. 
 
6.1.3 Illicit drug and premature loss of life 
Although the average PYLL per decedent in this cohort (36.2 years) was higher than 29 
years reported among Australian drug users (Degenhardt et al. 2014) and 18.3 years 
among drug users in United States of America (Smyth et al. 2007), these indicators are not 
directly comparable because both studies used 65 years cut-off age instead of 70 years cut-
off. However, overdose was the largest contributor to PYLL in all the studies, and suicide 
was also the second leading cause of PYLL in the Australian cohort.  Hence, measures 
targeting overdose and suicide are top priorities for reducing loss of potential life years. 
The PYLL estimation by gender showed that the average life years lost per female 
decedent were higher than those of male drug users, even though there were higher 
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absolute numbers of deaths among males than females. This implies that female drug 
users died at a very young age. This finding is a concern because female drug users were 
fewer than males in this cohort of treatment seekers which suggested that a smaller 
percentage of female drug users were accessing services but they seemed to experience 
death more prematurely  (on average) than their male counterparts. Treatment approaches 
focusing on the needs of female drug users would help to reduce adverse health 
consequences (Greenfield & Grella 2009), for example, separate women-only programmes, 
women-specific services within mixed-gender programmes, having female staff attend to 
female drug users, addressing any identified barriers to women’s treatment participation, 
and rendering other support to women as needed. Granted that women appear to need 
further attention, it is important to note that men in this cohort had the highest numbers of 
deaths, and lost the highest overall numbers of lost life years. This situation calls for even 
greater attention to men so as to forestall future premature loss of lives. 
     In terms of primary drug reported at baseline, stimulant users contributed the most to 
the total PYLL, followed by opiates, and this means that they will require more support to 
reduce harm. Few deaths occurred among the subgroup of clients that reported cannabis 
as their primary drug at the initial interview but they had the highest mean PYLL, which 
signified that the deceased clients died at younger age relative to others. Cannabis is 
considered to be less harmful than other drugs, and Degenhardt et al. (2013) reported that 
cannabis dependence was not a contributor to years of life lost. This unexpected finding 
could be explained by other factors. Unpublished data from this cohort showed that 
clients in the cannabis subgroup were younger at baseline (mean 20.2 years) than those in 
the other primary drug subgroups, they died at a younger age (mean 27.4 years) than 
others, and had a high proportion of multiple drug users just like other primary drug 
subgroups. It is also possible that these cannabis users switched over to more harmful 
drug use patterns during the follow-up period. 
     Findings from this study concerning PYLL among drug users could not be compared to 
any similar data from Finland. Although Vohlonen et al. (2007) have written a paper to 
compare PYLL in the general population of Finland to different countries in Europe and 
North America, the estimates are not comparable because the data were not from drug 
users in general or treatment-seeking drug users.  
 
6.1.4 Route of drug administration and deaths 
Mortality studies based upon the route of drug administration (ROA) are scarce. In study 
IV, data analysis was restricted only to primary users of opiates and stimulants. The fully 
adjusted multivariate Cox model showed that there was a statistically significant 
association between route of administration and all-cause deaths. The risk for all-cause 
death was lower among smokers compared to I.V. users (aHR: 0.52 (95%CI: 0.28–0.97). In 
other words, the risk of death was higher in those clients who reported I.V. drug use at 
baseline relative to smokers. Granted that the smokers had lower risk of death than 
injectors, it does not necessarily imply that smoking is a harmless way to use drugs. This 
finding could possibly be because clients who administered drug through I.V. route 
greatly outnumbered all the other routes in this cohort and as such, 251 out of the 330 
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deaths occurred in I.V. users. It is not known if the results would be the same or different 
if other ROA were equally represented in the study sample.  
     It is difficult to compare the study findings to those from other studies because most of 
them have solely focused on injectors (Mathers & Degenhardt 2014; Mathers et al. 2013; 
Degenhardt et al. 2006), and some others considered non-injectors as a single group (Quan 
et al. 2007). Among the few studies that considered mortality based upon various routes 
such as injecting, smoking, snorting, and oral consumption (Darke & Ross 2000; Thiblin et 
al. 2004), they did not test for the risk of all-cause deaths. To the best of my knowledge, 
similar studies on the association between the individual routes of drug administration 
and all-cause deaths among drug users were not available in Finland for comparison. This 
highlighted a need for more studies that give attention to deaths among persons who use 
drugs through various individual non-injecting routes in addition to injecting routes. 
     In this cohort, deaths occurred within all categories of route of drug administration but 
I.V. users had a higher risk of all-cause death than smokers.  Abstinent from drug use will 
be a definite measure to prevent untimely deaths from drug use. However, other measures 
have been proposed for clients who are unable to stop or who are undecided about 
stopping drug use, ranging from measures to address transition from injecting to non-
injecting routes (Gossop et al., 2004; Des Jarlais et al., 2014) to those that prevent initiation 
of injecting among non-injectors and the resumption of injecting among former injectors 
(Neaigus et al., 2006). 
 
 
6.2 STRENGTHS AND LIMITATIONS OF THE STUDY  
 
The strengths of the present study include the large sample size of the cohort which 
increased the statistical power to detect subgroup differences. The long follow-up period 
allowed enough time to study the negative health consequences of drug use. It has been 
documented that the Finnish health register system has good coverage and validity 
(Gissler & Haukka 2004). Linkage to the comprehensive Cause of Death Register provided 
a cost-effective access to high-quality data and ensured that there was no loss to follow-up. 
The availability of clients’ information at baseline enabled proper interpretation of the 
mortality data. This study thoroughly evaluated deaths that occurred in the cohort using a 
combination of traditional mortality indicators such as death counts, CMRs, and SMRs, 
and a non-traditional indicator such as PYLL which enabled measurement of the 
prematurity of those deaths and identification of priority areas for prevention and 
intervention. 
     This research adopted a positivist scientific research philosophy (Gill & Johnson 2002) 
which assumes that knowledge is objective and measurable and emphasises the use of 
numbers and quantitative information analysed using statistical techniques. It was further 
strengthened by the use of deductive research approach (Gill & Johnson 2002) whereby 
the researcher initiates the research work based upon existing knowledge/theory, creates a 
hypothesis, and then tests it on study sample in order to prove or disprove the theory.   
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     The study has some weaknesses as well. Treatment-seeking illicit drug users may differ 
systematically from non-treatment seekers. Hence our results have limited generalisability 
to non-treatment seekers. All consecutive clients who sought treatment at HDI were 
studied, so it could be argued that selection bias might not be a major limitation of this 
study. On the other hand, the data used for this study came from a single treatment centre 
and as such, were not representative of all the treatment centres, treatment-seeking clients, 
and all illicit drug users in Helsinki and in Finland as a whole. Nevertheless, previous 
report using administrative data has shown that 50-60% of all problem drug users were 
from the southern part of Finland and that over half of them were from the Greater 
Helsinki area (Forsell et al. 2010; Forsell & Nurmi 2015).  
     Since clients self-reported their baseline information, there are possibilities for 
information and response bias due to the illegal nature of the substances they were using 
and the stigma associated with drug use. However, it has been demonstrated that self-
reported information by drug users is highly reliable (Kokkevi et al. 1997) and that drug 
users are willing to discuss stigmatised behaviours such as sharing injecting equipment 
(Beynon et al. 2010b). Although the use of baseline variables to interpret the mortality data 
provided rich information, it is an important limitation of our study. It is possible that 
some clients in our cohort might have changed some of their drug use patterns during the 
follow-up period.  
     Furthermore, the use of 70 years as the cut-off age for PYLL estimation might have led 
to under-estimation of the actual PYLL in the cohort. Seventy years was chosen because it 
was the cut-off age used by Organisation for Economic Co-operation and Development 
(OECD) for estimating PYLL (OECD 2014). More so, health policy experts have used this 
same cut-off age in previous PYLL estimation among persons from the general population 
of Finland (Vohlonen et al. 2007).  
     Opponents have criticised positivist approach as adopting over-deterministic 
orientation towards understanding human actions while deductive approach is deemed to 
be researcher-led and restricts respondents to pre-conceived questions (Gill & Johnson 
2002). However, the large sample size, and the nature of the data used for this study (i.e. 
secondary data) precluded the use of interpretivist and inductive approaches like 
interviews and other qualitative techniques.  
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7 Conclusions 
 
Based on the findings from these four studies, the following conclusions were made: 
 
1. Risky or problematic drug use behaviours were common in the cohort as evidenced 
by I.V. and frequent administration of primary drug, and multiple drug use. 
Opiates were more common among males and stimulants were more common 
among females. Treatment seeking by stimulant users declined after 2000 while 
opiate users increased during the same period. 
 
2. There was nearly 9-fold risk of death among drug users relative to persons in the 
general population of Finland of the same age and gender. Excess mortality was 
higher among female drug users compared to males. Overall death rates declined at 
the end of the follow-up period. 
 
3. Drug users died prematurely at very young age resulting in high PYLL before 70 
years. On average, female drug users lost more life years, with higher mean PYLL 
than males but men lost the highest total number of life years. The two top-ranking 
causes of PYLL were accidental overdose and suicide. Overall, stimulants 
contributed the most to the loss of life years relative to other primary drugs, 
followed by opiates. 
 
4. Although I.V. users were disproportionately affected, clients who smoked, snorted, 
and orally consumed their drugs at baseline also experienced deaths. Smoking 
decreased the risk of all-cause death in comparison to I.V. route. The risks of all-
cause death among snorters and oral users were not statistically significantly 
different from that of I.V. users.  
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8 Recommendations 
 
8.1 RECOMMENDATIONS FOR PRACTICE 
 
 In view of the general decline in treatment seeking at HDI, practical measures 
would be necessary to attract persons in need of treatment. For example, creation of 
awareness about the new site, assistance with transport costs, and any other 
measures that might boost attendance.   
 
 Female drug users would require further support and gender-sensitive treatment 
approach would be necessary, for example, women-specific treatment contents or 
services within the currently existing mixed-gender programmes.  
 
 This study demonstrated that measures targeting accidental overdose and suicide 
are the two top-ranking priority areas for reducing untimely deaths among drug 
users. For example, drug education highlighting the danger of drug mixing and 
overdose management techniques, and greater support for those with comorbid 
mental health problems.  
 
 I.V. drug users experienced more deaths than clients who administered drugs 
through other routes. Measures to prevent transition from injecting to non-injecting 
routes would be necessary. Interventions to reduce risky injecting behaviours (for 
example, increasing access to opioid substitution therapy, and education to provide 
information about health risks, and to discourage sharing of used injecting 
equipment) in addition to needle and syringe programmes will help to reduce 
health harms. 
 
 Deaths also occurred within all the categories of non-I.V. routes of drug 
administration.  Therefore, clients using drugs through non-I.V. routes will also 
benefit from drug education focusing on dangers of drug mixing, reducing the 
frequency and quantity of drugs used, and ultimately abstinence from drug use. 
 
 
 
 
 
 
 
53 
 
    
 
8.2 RECOMMENDATIONS FOR FUTURE RESEARCH 
 
 There were fewer female than male treatment-seekers, and female drug users had 
higher excess mortality and also higher mean PYLL per decedent than males. There 
is a need for future research studies to assess if women in general, and indeed any 
subgroups of women, face any barriers to drug abuse treatment. For example, a 
qualitative research using interpretivist approach in order to understand women’s 
perceptions of drug use, treatment and barriers to treatment participation. A mixed 
methods research incorporating both qualitative and quantitative methodology 
could also be helpful.  
 
 Older drug users were few in this cohort. Further studies would be necessary to 
investigate if older persons who use drugs experience any barriers to treatment 
seeking, if those already in contact with treatment services encounter any barriers, 
and to identify the best ways to reduce such barriers. A qualitative research using 
interpretivist approach might be best suited for such studies since there seems to be 
few older people in the general population who use drugs. Hence, qualitative 
technique will help researchers to obtain deeper insights into the experiences, 
opinions and feelings of older drug users. 
 
 Being that accidental overdose was the single most important cause of death, 
further studies are needed to explore means of addressing accidental overdose. 
Research studies conducted in other countries have documented positive results 
with take-home emergency naloxone and overdose response/management training 
(Lankenau et al. 2013; Strang et al. 2008) such as reduction in the rate of overdose 
deaths. Future studies could explore to see if such successes could be reproduced in 
Finland (especially among users of full opioid agonists) alongside with identifying 
factors that might hinder drug users from applying the overdose response 
techniques. 
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